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1. INTRODUCTION 
Amongst the various routes of drug delivery, oral route is perhaps the most 
preferred to the patient and the clinician alike. However, peroral administration of 
drugs has disadvantages such as hepatic first pass metabolism and enzymatic 
degradation within the GI tract, that prohibit oral administration of certain classes of 
drugs especially peptides and proteins. Consequently, other absorptive mucosae are 
considered as potential sites for drug administration. Transmucosal routes of drug 
delivery (i.e., the mucosal linings of the nasal, rectal, vaginal, ocular, and oral cavity) 
offer distinct advantages over peroral administration for systemic drug delivery. 
These advantages include possible bypass of first pass effect, avoidance of 
presystemic elimination within the GI tract, and, depending on the particular drug, a 
better enzymatic flora for drug absorption. 
The nasal cavity as a site for systemic drug delivery has been investigated by 
many research groups and the route has already reached commercial status with 
several drugs including- LHRH and calcitonin. However, the potential irritation and 
the irreversible damage to the ciliary action of the nasal cavity from chronic 
application of nasal dosage forms, as well as the large intra- and inter-subject 
variability in mucus secretion in the nasal mucosa, could significantly affect drug 
absorption from this site. Even though the rectal, vaginal, and ocular mucosae all offer 
certain advantages, the poor patient acceptability associated with these sites renders 
them reserved for local applications rather than systemic drug administration. The oral 
cavity, on the other hand, is highly acceptable by patients, the mucosa is relatively 
permeable with a rich blood supply, it is robust and shows short recovery times after 
stress or damage and the virtual lack of Langerhans cells makes the oral mucosa 
tolerant to potential allergens. 
Furthermore, oral transmucosal drug delivery bypasses first pass effect and 
avoids pre-systemic elimination in the GI tract. These factors make the oral mucosal 
cavity a very attractive and feasible site for systemic drug delivery (Squier C.A., 
1991). 
• Within the oral mucosal cavity, delivery of drugs is classified into three 
categories: 
• Sublingual delivery, which is systemic delivery of drugs through the mucosal 
membranes lining the floor of the mouth, 
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• Buccal delivery, which is drug administration through the mucosal membranes 
lining the cheeks (buccal mucosa), and 
• Local delivery, which is drug delivery into the oral cavity. 
1.1 OVERVIEW OF THE ORAL MUCOSA 
1.1.1 Structure 
The oral mucosa is composed of an outermost layer of stratified squamous 
epithelium (Figure 1). Below this lies a basement membrane, a lamina propria 
followed by the sub mucosa as the innermost layer. The epithelium is similar to 
stratified squamous epithelia found in the rest of the body in that it has a mitotically 
active basal cell layer, advancing through a number of differentiating intermediate 
layers to the superficial layers, where cells are shed from the surface of the 
epithelium. The epithelium of the buccal mucosa is about 40-50 cell layers thick, 
while that of the sublingual epithelium contains somewhat fewer. The epithelial cells 
increase in size and become flatter as they travel from the basal layers to the 
superficial layers. The turnover time for the buccal epithelium has been estimated at 
5-6 days and this is probably representative of the oral mucosa as a whole. The oral 
mucosal thickness varies depending on the site: the buccal mucosa measures at 500-
800 µm, while the mucosal thickness of the hard and soft palates, the floor of the 
mouth, the ventral tongue, and the gingivae measure at about 100-200 µm. The 
composition of the epithelium also varies depending on the site in the oral cavity. The 
mucosae of areas subject to mechanical stress (the gingivae and hard palate) are 
keratinized similar to the epidermis (Wertz P.W. et.al., 1991). 
The mucosae of the soft palate, the sublingual, and the buccal regions, 
however, are not keratinized. The keratinized epithelia contain neutral lipids like 
ceramides and acylceramides which have been associated with the barrier function. 
These epithelia are relatively impermeable to water. In contrast, non-keratinized 
epithelia, such as the floor of the mouth and the buccal epithelia do not contain 
acylceramides and only have small amounts of ceramides. They also contain small 
amounts of neutral but polar lipids, mainly cholesterol sulfate and glucosyl ceramides. 
These epithelia have been found to be considerably more permeable to water than 
keratinized epithelia (Harris, D. et.al., 1992). 
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Figure 1.Structure of the oral mucosae. 
 
 
 
1.2 Permeability 
The oral mucosa in general is somewhat leaky epithelia intermediate between 
that of the epidermis and intestinal mucosa. It is estimated that the permeability of the 
buccal mucosa is 4-4000 times greater than that of the skin. As indicative by the wide 
range in this reported value, there are considerable differences in permeability 
between different regions of the oral cavity because of the diverse structures and 
functions of the different oral mucosae. In general, the permeabilities of the oral 
mucosae decrease in the order of sublingual greater than buccal and buccal greater 
than palatal. This rank order is based on the relative thickness and degree of 
keratinization of these tissues, with the sublingual mucosa being relatively thin and 
non-keratinized, the buccal thicker and non-keratinized, and the palatal intermediate 
in thickness but keratinized (Galey, W.R. et.a.l, 1976). It is currently believed that the 
permeability barrier in the oral mucosa is a result of intercellular material derived 
from the so-called ‘membrane coating granules’ (MCG). When cells go through 
differentiation, MCGs start forming and at the apical cell surfaces they fuse with the 
plasma membrane and their contents are discharged into the intercellular spaces at the 
upper one third of the epithelium. This barrier exists in the outermost 200µm of the 
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superficial layer. Permeation studies have been performed using a number of very 
large molecular weight tracers, such as horseradish peroxidase and lanthanum nitrate. 
When applied to the outer surface of the epithelium, these tracers penetrate only 
through outermost layer or two of cells. When applied to the sub mucosal surface, 
they permeate up to, but not into, the outermost cell layers of the epithelium. 
According to these results, it seems apparent that flattened surface cell layers present 
the main barrier to permeation, while the more isodiametric cell layers are relatively 
permeable. In both keratinized and non-keratinized epithelia, the limit of penetration 
coincided with the level where the MCGs could be seen adjacent to the superficial 
plasma membranes of the epithelial cells. Since the same result was obtained in both 
keratinized and non-keratinized epithelia, keratinization by itself is not expected to 
play a significant role in the barrier function. The components of the MCGs in 
keratinized and non-keratinized epithelia are different, however (Hill, M.W. et.al., 
1979). The MCGs of keratinized epithelium are composed of lamellar lipid stacks, 
whereas the non-keratinized epithelium contains MCGs that are non-lamellar. The 
MCG lipids of keratinized epithelia include sphingomyelin, glucosyl ceramides, 
ceramides, and other nonpolar lipids, however for non-keratinized epithelia, the major 
MCG lipid components are cholesterol esters, cholesterol, and glycosphingolipids. 
Aside from the MCGs, the basement membrane may present some resistance to 
permeation as well, however the outer epithelium is still considered to be the rate 
limiting step to mucosal penetration. The structure of the basement membrane is not 
dense enough to exclude even relatively large molecules (Gandhi, R.B. et.al., 1994). 
The cells of the oral epithelia are surrounded by an intercellular ground 
substance, mucus, the principle components of which are complexes made up of 
proteins and carbohydrates. These complexes may be free of association or some 
maybe attached to certain regions on the cell surfaces. This matrix may actually play a 
role in cell-cell adhesion, as well as acting as a lubricant, allowing cells to move 
relative to one another. Along the same lines, the mucus is also believed to play a role 
in bioadhesion of mucoadhesive drug delivery systems. In stratified squamous 
epithelia found elsewhere in the body, mucus is synthesized by specialized mucus 
secreting cells like the goblet cells, however in the oral mucosa; mucus is secreted by 
the major and minor salivary glands as part of saliva. Up to 70% of the total mucin 
found in saliva is contributed by the minor salivary glands. At physiological pH the 
mucus network carries a negative charge (due to the sialic acid and sulfate residues) 
     INTRODUCTION 
Department of Pharmaceutics Page 5 
which may play a role in mucoadhesion. At this pH mucus can form a strongly 
cohesive gel structure that will bind to the epithelial cell surface as a gelatinous layer 
(Peppas, N.A. et.al., 1985). 
Another feature of the environment of the oral cavity is the presence of saliva 
produced by the salivary glands. Saliva is the protective fluid for all tissues of the oral 
cavity. It protects the soft tissues from abrasion by rough materials and from 
chemicals. It allows for the continuous mineralization of the tooth enamel after 
eruption and helps in remineralisation of the enamel in the early stages of dental 
caries. Saliva is an aqueous fluid with 1% organic and inorganic materials. The major 
determinant of the salivary composition is the flow rate which in turn depends upon 
three factors: the time of day, the type of stimulus, and the degree of stimulation. The 
salivary pH ranges from 5.5 to 7 depending on the flow rate. At high flow rates, the 
sodium and bicarbonate concentrations increase leading to an increase in the pH. The 
daily salivary volume is between 0.5 to 2 liters and it is this amount of fluid that is 
available to hydrate oral mucosal dosage forms. A main reason behind the selection of 
hydrophilic polymeric matrices as vehicles for oral transmucosal drug delivery 
systems is this water rich environment of the oral cavity (Rathbone, M. et.al., 1994). 
1.2.1 Permeation Enhancers 
Membrane permeation is the limiting factor for many drugs in the 
development of buccal adhesive delivery devices. The epithelium that lines the buccal 
mucosa is a very effective barrier to the absorption of drugs. Substances that facilitate 
the permeation through buccal mucosa are referred as permeation enhancers 
(Chattarajee, et al., 1995). As most of the penetration enhancers were originally 
designed for purposes other than absorption enhancement, a systemic search for safe 
and effective penetration enhancers must be a priority in drug delivery. The goal of 
designing penetration enhancers, with improved efficacy and reduced toxicity profile 
is possible by understanding the relationship between enhancer structure and the 
effect induced in the membrane and of course, the mechanism of action. However, the 
selection of enhancer and its efficacy depends on the physicochemical properties of 
the drug, site of administration, nature of the vehicle and other excipients. In some 
cases usage of enhancers in combination has shown synergistic effect than the 
individual enhancers. The efficacy of enhancer in one site is not same in the other site 
because of differences in cellular morphology, membrane thickness, enzymatic 
activity, lipid composition and potential protein interactions are structural and 
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functional properties. Penetration enhancement to the buccal membrane is drug 
specific (Shojaei 1998).Effective penetration enhancers for transdermal or intestinal 
drug delivery may not have similar effects on buccal drug delivery because of 
structural differences; however, enhancers used to improve drug permeation in other 
absorptive mucosae improve drug penetration through buccal mucosa. These 
permeation enhancers should be safe and non toxic, pharmacologically and 
chemically inert, non-irritant, and non-allergenic (Aungst 1994). However, 
examination of penetration route for transbuccal delivery is important because it is 
fundamental to select the proper penetration enhancer to improve the drug 
permeability. The different permeation enhancers available are listed in Table.1. (Lee 
1991).\ 
Table 1.List of permeation enhancers. 
 Permeation Enhancers 
Chelators EDTA, 
Citricacid , 
Sodium salicylate, 
Methoxy salicylates. 
Surfactants Sodium lauryl sulphate, 
Polyoxyethylene, 
Polyoxyethylene-9-laurylether, 
Polyoxythylene-20-cetylether, 
Benzalkonium chloride, 
23-lauryl ether, 
Cetylpyridinium chloride, 
Cetyltrimethyl ammonium bromide. 
Bile salts Sodium glycocholate, 
Sodium deoxycholate, 
Sodium taurocholate, 
Sodium glycodeoxycholate, 
Sodium taurodeoxycholate. 
Fatty acids Oleic acid, 
Capric acid, 
Lauric acid, 
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Lauric acid/ propylene glycol, 
Methyloleate, 
Lysophosphatidylcholine, 
Phosphatidylcholine. 
Non-surfactants Unsaturated cyclic ureas. 
Inclusion complexes Cyclodextrins 
Others Aprotinin, 
Azone, 
Cyclodextrin, 
Dextran sulfate, 
Menthol, 
Polysorbate 80, 
Sulfoxides and various alkyl glycosides. 
Thiolated polymers Chitosan-4-thiobutylamide, 
Chitosan- 4-thiobutylamide/gsh, 
Chitosan-cysteine, 
Poly (acrylic acid)-homocysteine, 
Polycarbophil-cysteine, 
Polycarbophil-cysteine/gsh, 
Chitosan-4-thioethylamide/gsh, 
Chitosan- 4-thioglycholic acid. 
 
1.3 Buccal Mucoadhesive Polymers 
Polymer is a generic term used to describe a very long molecule consisting of 
structural units and repeating units connected by covalent chemical bonds. The term is 
derived from the Greek words: polys meaning many, and meros meaning parts .Many 
Studies showed that addition of various polymers to Drug Delivery System, such as 
gums, increased the duration of attachment of the Medicinal Formulations to the 
mucous surface and increased the efficacy of antibiotic treatment (Salamat et al., 
2005). The development of the mucoadhesion theory and improvements in practical 
methods were accompanied by investigation of many polymers used in 
pharmaceuticals and new materials and their mixtures for the presence of 
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mucoadhesive properties. The classification of mucoadhesive polymers and examples 
are presented in Table-2. 
Bioadhesive formulations use polymers as the adhesive component. These 
formulations are often water soluble and when in a dry form attract water from the 
biological surface and this water transfer leads to a strong interaction. These polymers 
also form viscous liquids when hydrated with water that increases their retention time 
over mucosal surfaces and may lead to adhesive interactions. Bioadhesive polymers 
should possess certain physicochemical features including hydrophilicity, numerous 
hydrogen bond-forming groups, flexibility for interpenetration with mucus and 
epithelial tissue, and visco-elastic properties (Batchelor, 2004). 
1.3.1 Ideal Characteristics of a Buccal Adhesive Polymer 
 Polymer and its degradation products should be non-toxic, non-irritant and 
free from leachable impurities. 
 Should have good spread ability, wetting, swelling and solubility and 
biodegradability properties. 
 pH should be biocompatible and should possess good viscoelastic properties. 
 Should adhere quickly to buccal mucosa and should possess sufficient 
mechanical strength. 
 Should possess peel, tensile and shear strengths at the bioadhesive range. 
 Polymer must be easily available and its cost should not be high. 
 Should show bioadhesive properties in both dry and liquid state. 
 Should demonstrate local enzyme inhibition and penetration enhancement 
properties. 
 Should demonstrate acceptable shelf life. 
 Should have optimum molecular weight. 
 Should possess adhesively active groups. 
 Should have required spatial conformation. 
 Should be sufficiently cross-linked but not to the degree of suppression of 
bond forming groups. 
 Should not aid in development of secondary infections such as dental caries. 
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Table 2.Classification of mucoadhesive polymers,(Salamat et al., 2005). 
Property  used for 
classification 
Source Examples 
Source Natural and 
modified natural 
polymers 
 
 
 
 
 
Synthetic 
Agarose, 
Chitosan, 
Gelatin, 
Hyaluronic acid, 
Carrageenan, 
Pectin, 
Sodium alginate. 
Cellulose derivatives 
CMC, 
thiolated CMC, 
Na CMC, 
hydroxyethylcellulose, 
HPC, HPMC, methylcellulose, 
Methylhydroxyethylcellulose. 
Polymers based on 
poly(meth)acrylic acid. 
Carbopol, 
Polycarbophil, 
Polyacrylic acid, 
Polyacrylates, 
Copolymer of acrylic acid and 
PEG, 
Copolymer of methylvinyl ether and 
Methacrylic acid, 
Poly-2-hydroxyethylmethacrylate, 
Copolymer of acrylic acid and 
Ethylhexylacrylate, 
Polymethacrylate, 
Polyalkylcyanoacrylates:- 
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Polyisobutylcyanoacrylate, 
Polyisohexylcyanoacrylate. 
Others 
Poly-N-2-
hydroxypropylmethacrylamide, 
Polyhydroxyethylene, 
PVA, PVP, 
Thiolated polymers 
Solubility in water Water-soluble 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cellulose derivatives 
CMC, 
Thiolated CMC, 
Na CMC, 
Hydroxyethylcellulose, 
HPC, HPMC, 
Methylcellulose, 
Methylhydroxyethylcellulose. 
Polymers based on 
poly(meth)acrylic acid 
Carbopol, 
Polycarbophil, 
Polyacrylic acid, 
Polyacrylates, 
Copolymer of acrylic acid and 
PEG, 
Copolymer of methylvinyl ether and 
Methacrylic acid, 
Poly-2-hydroxyethylmethacrylate, 
Copolymer of acrylic acid and 
Ethylhexylacrylate, 
Polymethacrylate, 
Polyalkylcyanoacrylates:- 
Polyisobutylcyanoacrylate, 
Polyisohexylcyanoacrylate. 
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Water-insoluble 
Others 
Poly-N-2-
hydroxypropylmethacrylamide, 
Polyhydroxyethylene, 
ethylcellulose, 
PVA, PVP, Thiolated polymers. 
 
 
Charge 
Cationic 
Anionic 
 
 
Uncharged 
Aminodextran, 
dimethylaminoethyldextran, 
chitosan, quaternized chitosan 
Chitosan-EDTA, PAC, carbopol, 
polycarbophil, pectin, sodium 
alginate, Na CMC, CMC 
Hydroxyethylated starch, HPC, 
PEG, PVA, PVP 
Possible mechanism of 
formation of 
Bioadhesive 
Bonds 
Covalent 
Hydrogen bonds 
Electrostatic 
interactions 
Cyanoacrylate 
Acrylates, carbopol, polycarbophil, 
PVA 
Chitosan 
Notes. CMC = carboxymethylcellulose; HPMC = hydroxypropylmethylcellulose; 
PEG = polyethylene glycol; PVA = polyvinyl alcohol; PVP = polyvinylpyrrolidone; 
HEC = hydroxyethylcellulose; HPC = hydroxypropylcellulose; PAA = polyacrylic 
acid; EDTA = ethylenediaminetetraacetate. 
1.4 Mechanisms of mucoadhesion 
The mechanism of adhesion of certain macromolecules to the surface of a 
mucous tissue is not well understood yet. The mucoadhesive must spread over the 
substrate to initiate close contact and increase surface contact, promoting the diffusion 
of its chains within the mucus. Attraction and repulsion forces arise and, for a 
mucoadhesive to be successful, the attraction forces must dominate. Each step can be 
facilitated by the nature of the dosage form and how it is administered. For example, a 
partially hydrated polymer can be absorbed by the substrate because of the attraction 
by the surface water (Lee, Park, Robinson et al., 2000). 
Thus, the mechanism of mucoadhesion is generally divided in two steps, the 
contact stage and the consolidation stage (Figure 1). The first stage is characterized 
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bythe contact between the mucoadhesive and the mucous membrane, with spreading 
and swelling of the formulation, initiating its deep contact with the mucus layer 
(Hagerstrom, 2003). In some cases, such as for ocular or vaginal formulations, the 
delivery system is mechanically attached over the membrane. In other cases, the 
deposition is promoted by the aerodynamics of the organ to which the system is 
administered, such as for the nasal route. On the other hand, in the gastrointestinal 
tract direct formulation attachment over the mucous membrane is not feasible. 
Peristaltic motions can contribute to this contact, but there is little evidence in the 
literature showing appropriate adhesion. Additionally, an undesirable adhesion in the 
esophagus can occur. In these cases, mucoadhesion can be explained by peristalsis, 
the motion of organic fluids in the organ cavity, or by Brownian motion. If the 
particle approaches the mucous surface, it will come into contact with repulsive forces 
(osmotic pressure, electrostatic repulsion, etc.) and attractive forces (van der Waals 
forces and electrostatic attraction). Therefore, the particle must overcome this 
repulsive barrier (Smart, 2005). 
In the consolidation step (Figure 1), the mucoadhesive materials are activated 
by the presence of moisture. Moisture plasticizes the system, allowing the mucoadhe-
sive molecules to break free and to link up by weak van der Waals and hydrogen 
bonds (Smart, 2005). Essentially, there are two theories explaining the consolidation 
step: the diffusion theory and the dehydration theory. According to diffusion theory, 
the mucoadhesive molecules and the glycoproteins of the mucus mutually interact by 
means of interpenetration of their chains and the building of secondary bonds (Smart, 
2005). For this to take place the mucoadhesive device has features favoring both 
chemical and mechanical interactions. For example, molecules with hydrogen bonds 
building groups (–OH, –COOH), with an anionic surface charge, high molecular 
weight, flexible chains and surface-active properties, which induct its spread 
throughout the mucus layer, can present mucoadhesive properties (Mathiowitz, 
Chickering, Lehr, 1999). 
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Figure 2 – The two steps of the mucoadhesion process. 
 
 
 
 
 
 
 
 
 
According to dehydration theory, materials that are able to readily gelify in an 
aqueous environment, when placed in contact with the mucus can cause its 
dehydration due to the difference of osmotic pressure. The difference in concentration 
gradient draws the water into the formulation until the osmotic balance is reached. 
This process leads to the mixture of formulation and mucus and can thus increase 
contact time with the mucous membrane. Therefore, it is the water motion that leads 
to the consolidation of the adhesive bond, and not the interpenetration of 
macromolecular chains. However, the dehydration theory is not applicable for solid 
formulations or highly hydrated forms (Smart, 2005). 
Figure 3 – Dehydration theory of mucoadhesion. 
 
                
 
1.5 Theories of Bioadhesion 
Although the chemical and physical basis of mucoadhesion are not yet well 
understood, there are six classical theories adapted from studies on the performance of 
several materials and polymer-polymer adhesion which explain the phenomenon 
(Hagerstrom, 2003; Huang et al., 2000),(Smart, 2005). 
Electronic theory 
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Electronic theory is based on the premise that both mucoadhesive and 
biological materials possess opposing electrical charges. Thus, when both materials 
come into contact, they transfer electrons leading to the building of a double 
electronic layer at the interface, where the attractive forces within this electronic 
double layer determines the mucoadhesive strength (Mathiowitz, Chickering, Lehr, 
1999). 
Adsorption theory 
According to the adsorption theory, the mucoadhesive device adheres to the mucus by 
secondary chemical interactions, such as in van der Waals and hydrogen bonds, 
electrostatic attraction or hydrophobic interactions. For example, hydrogen bonds are 
the prevalent interfacial forces in polymers containing carboxyl groups (Hagerstrom, 
2003; Huanget al., 2000; Lee, Park, Robinson, 2000; Smart, 2005). Such forces 
have been considered the most important in the adhesive interaction phenomenon 
(Smart, 2005) because, although they are individually weak, a great number of 
interactions can result in an intense global adhesion (Mathiowitz, Chickering, Lehr, 
1999). 
Figure 4 – Absorption theory of mucoadhesion. 
 
 
 
 
 
 
 
 
 
 
 
 
WETTING THEORY OF MUCOADHESION 
Wetting theory 
The wetting theory applies to liquid systems which present affinity to the 
surface in order to spread over it. This affinity can be found by using measuring 
techniques such as the contact angle. The general rule states that the lower the contact 
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angle then the greater the affinity. The contact angle should be equal or close to zero 
to provide adequate spreadability (Mathiowitz, Chickering, Lehr, 1999). 
 
Diffusion theory 
Diffusion theory describes the interpenetration ofboth polymer and mucin 
chains to a sufficient depth to create a semi-permanent adhesive bond . It is believed 
that the adhesion force increases with the degree of penetration of the polymer chains 
(Mathiowitz, Chickering, Lehr, 1999). This penetration rate depends on the 
diffusion coefficient, flexibility and nature of the mucoadhesive chains, mobility and 
contact time (Hägerström, 2003; Huanget al., 2000; Lee, Park, Robinson, 2000; 
Smart, 2005). 
Figure 4 – Diffusion theory of mucoadhesion. 
 
DIFFUSION THEORY OF MUCOADHESION 
Various classes of polymers have been investigated in order to meet the requirements 
for a mucoadhesive polymer, such as proper hydrogen-bonding functional groups, 
suitable wetting properties, swelling/water load properties, and sufficient flexibility 
for entanglement with the tissue mucus network. Derivatives of cellulose (methyl-, 
Hydroxypropyl carboxymethylcellulose) and poly (acrylic acid) with high molecular 
weight (polycarbophil, carbomer) (Park H., et.al., 1987) have been shown to possess 
the hydrogel-forming properties, which are necessary for mucoadhesion. 
Polysaccharides, such as chitosan, are among the newer mucoadhesive polymers. 
There have also been some recent reports of protein mucoadhesion, in which 
proteins are able to non-specifically adhere to almost any kind of surfaces. One 
example of such a protein is the 74-residue adhesive protein, which is deposited into 
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the byssal attachment pads of Mytilus edulis (common mussel) and enables this 
marine invertebrate to adhere to the desired surfaces. 
The mucosal surfaces are covered with a mucus layer, in which mucins are the 
major component. Mucins are highly glucosylated glycoproteins with a large peptide 
backbone and oligosaccharides as side chains. Their protein backbone is characterized 
by the presence of repeating sequences rich in serine, threonine, and proline residues. 
Many of the O-linked oligosaccharide side chains are often terminated in either sialic 
acid, sulfonic acid, or l-fructose (Gandhi, R.B, et.al., 1994). 
As a result, mucins are negatively charged at physiological pH. Mechanisms 
of polymer attachment to mucosal surfaces are not yet fully understood. However, 
certain theories of bioadhesion have suggested that it might occur via physical 
entanglement (diffusion theory) and/or chemical interactions, such as electrostatic, 
hydrophobic, hydrogen bonding, and Vander Waals’ interactions (adsorption and 
electronic theories). Positively charged polymers, such as chitosan, can bind to 
mucins via electrostatic interactions with the negatively charged sialic acid moieties. 
However, ionic interactions with sialic acid are merely one possible mechanism of 
polymer–mucin binding. 
In addition, it has been shown that anionic polymers usually provide better 
bioadhesion than cationic or uncharged polymers. Therefore, other mechanisms, 
including hydrophobic interactions, hydrogen bonding, and van der Waals’ 
interactions, are also possible, which probably involve other parts of the mucin 
molecules. Hydrogen bonds and hydrophobic interactions are typical of the types of 
interactions that are desirable for mucoadhesion. 
Recently, covalent bonds and disulfide bonds (through disulfide exchange 
reactions) have also been cited as contributing to the interactions responsible for 
mucoadhesion (Bernkop-Schnurch, et.al., 1999). Five theories have been suggested 
to play a major role in bioadhesion, namely, adsorption, diffusion, electronic, fracture, 
and wetting theories. In the adsorption theoryQ, primary and secondary chemical 
bonds of the covalent and non-covalent (electrostatic and vander Waals’ forces, 
hydrogen, and hydrophobic bonds) types are formed upon initial contact between the 
mucus and the mucoadhesive polymer. Most of the initial interfacials bonding forces 
are attributed to non-covalent forces. The formation of secondary chemical bonds 
greatly depends on properties of the polymer, which will be covered briefly in the 
next section. 
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The basis of the diffusion theoryQ is chain entanglement between 
glycoprotein’s of the mucus and the mucoadhesive polymer. Upon initial contact 
between these two polymers, diffusion of the bioadhesive polymer chain into the 
mucus network creates an entangled network between the two polymers. Sufficient 
polymer chain flexibility, adequate exposure for the surface contact of both polymers, 
similar chemical structures, and the diffusion coefficient of the bioadhesive polymer 
are among the factors which influence the inter-diffusion of the macromolecule 
network. 
The third theory is the electronic theoryQ. Because of different electronic 
properties of the mucoadhesive polymer and the mucus glycoprotein, electron transfer 
between these two surfaces occurs. Electron transfer contributes to formation of a 
charged double layer at the interface of the mucus and the polymer, which results in 
forces of attraction in this region and interdiffusion of the two surfaces. 
The fracture theory relates the force required for the detachment of polymers 
from the mucus to the strength of their adhesive bond. It has been found that the work 
fracture is greater when the network strands are longer or the degree of cross-linking 
is reduced. Finally, the bwetting theoryQ describes the ability of a bioadhesive 
polymer to spread on biological surfaces. This theory is predominantly applicable to 
liquid bioadhesive systems. Moderately wettable polymers have been shown to 
exhibit optimal adhesion to human endothelial cells (Wachem van P.B, et.al., 1985). 
1.6 Factors Affecting Mucoadhesion 
Mucoadhesion is a property for whose appearance both the bioadhesive 
polymer and the medium in which it is placed are important. The characteristics of 
themucoadhesive and the mucosa, as well as other factors which can influence the 
strength and duration of the mucoadhesive interaction are summarized in Table 3. 
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Table.No.3.Factors Affecting Mucoadhesion(NazilaSalamat-Milleret al., 2005). 
Factor Characteristics, examples 
Molecular weight 
Molecular weight Properties Of The Mucoadhesive 
Polymer 
Low-molecular-weight polymers 
penetrate the mucus layer better. High 
molecular weight promotes physical 
entangling. The optimum molecular 
weight is between 104 and 4 × 106 Dal. 
Polymers with higher molecular weights 
will not moisten quickly to expose free 
groups for interaction with the substrate, 
while polymers with low molecular 
weights will form loose gels or will 
dissolve quickly. For linear polymers, the 
mucoadhesion strength increases with 
increases in molecular weight, for 
example, mucoadhesive properties in a 
series of polyethylene glycols increased 
in the order: 2 × 104<2 × 105<4 × 105 . At 
the same time, dextran with very high 
molecular weight, ~2 × 107 , shows 
mucoadhesion similar to that of PEG with 
molecular weight 2 × 105 . This may 
result from the molecular conformation. 
Polymer chain flexibility Required for diffusion of chains and their 
entanglement with mucin. For polymers 
with high levels of linkage, the mobilities 
of the individual polymer chains decrease, 
leading to decreases in mucoadhesion 
strength. 
Ability to form hydrogen bonds Presence of functional groups able to 
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form hydrogen bonds (COOH, OH, etc.). 
Concentration Affects the availability for penetration of 
long polymer chains into the mucus layer; 
important mainly for liquid and viscous 
DDS. 
Extent of swelling of polymer or DDS Swelling of the polymer allows 
mechanical entangling because of the 
exposure of polymer chains and 
subsequent formation of hydrogen bonds 
and/or electrostatic interactions between 
the polymer and components of the 
mucosa. 
Environmental factors 
 
PH 
Changes in PH lead to differences in the 
extent of dissociation of functional groups 
in carbohydrate sequences or polypeptide 
amino acid sequences, as well as in the 
polymer. 
Pressure applied to the system for 
attachment 
Affects the depth of diffusion of chains. 
Cannot be controlled for systems used in 
the GIT. 
Duration of initial contact Determines the extent of swelling and 
diffusion of polymer chains. Cannot be 
controlled for systems used in the GIT. 
Moistening Moistening is required to allow the 
mucoadhesive polymer to spread over the 
surface and create a “macromolecular 
network” of sufficient size for the 
interpenetration of polymer and mucin 
molecules and to in crease the mobility of 
polymer chains.  However, there is a 
critical level of hydration for 
mucoadhesive polymers characterized by 
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optimum swelling and bioadhesion. 
Presence of metal ions Interaction with charged groups of 
polymers and/or mucus can decrease the 
number of interaction sites and the 
tightness of mucoadhesive bonding . 
Physiological factors 
Rate of renewal of mucosal cells Varies extensively for different types of 
mucosa. Limits the persistence of 
bioadhesive systems on mucosal surfaces. 
Concomitant diseases Can alter the physicochemical properties 
of mucus or its quantity (for example, 
hypo-and hyper secretion of gastric juice). 
Increases in body temperature, ulcer 
disease, colitis, tissue fibrosis, allergic 
rhinitis, bacterial or fungal infection, and 
inflammation. 
Tissue movement On consumption of liquid and food, 
speaking, peristalsis in the GIT. 
 
1.7 BUCCAL DRUG DELIVERY SYSTEMS 
Other than the low flux associated with buccal mucosal delivery, a major 
limitation of the buccal route of administration is the lack of dosage form retention at 
the site of absorption. Consequently, bioadhesive polymers have extensively been 
employed in buccal drug delivery systems. Bioadhesive polymers are defined as 
polymers that can adhere onto a biological substrate. The term mucoadhesion is 
applied when the substrate is mucosal tissue. Polymers which can adhere to either 
hard or soft tissue have been used for many years in surgery and dentistry. Diverse 
classes of polymers have been investigated for their potential use as mucoadhesive. 
These include synthetic polymers such as monomeric a cyanoacrylate, polyacrylic 
acid, Hydroxypropyl methylcellulose, and poly methacrylate derivatives as well as 
naturally occurring polymers such as hyaluronic acid and chitosan. Other synthetic 
polymers such as polyurethanes, epoxy resins, polystyrene, and natural-product 
cement have also been extensively investigated (Ch'ng, H.S., et.al., 1985). 
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In general, dosage forms designed for buccal administration should not cause 
irritation and should be small and flexible enough to be accepted by the patient. These 
requirements can be met by using hydrogels. Hydrogels are hydrophilic matrices that 
are capable of swelling when placed in aque1ous media. Normally, hydrogels are 
cross linked so that they would not dissolve in the medium and would only absorb 
water. When drugs are loaded into these hydrogels, as water is absorbed into the 
matrix, chain relaxation occurs and drug molecules are released through the spaces or 
channels within the hydrogel network. In a more broad meaning of the term, 
hydrogels would also include water-soluble matrices that are capable of swelling in 
aqueous media; these include natural gums and cellulose derivatives. These ‘pseudo-
hydrogels’ swell infinitely and the component molecules dissolve from the surface of 
the matrix. Drug release would then occur through the spaces or channels within the 
network as well as through the dissolution and/or the disintegration of the matrix. The 
use of hydrogels as adhesive preparations for transmucosal drug delivery has acquired 
considerable attention in recent years (Park K., et.al., 1984). 
The buccal mucosa offers several advantages for controlled drug delivery for 
extended periods of time. The mucosa is well supplied with both vascular and 
lymphatic drainage and first-pass metabolism in the liver and pre-systemic 
elimination in the gastrointestinal tract are avoided. The area is well suited for a 
retentive device and appears to be acceptable to the patient. With the right dosage 
form design and formulation, the permeability and the local environment of the 
mucosa can be controlled and manipulated in order to accommodate drug permeation. 
Buccal drug delivery is a promising area for continued research with the aim of 
systemic delivery of orally inefficient drugs as well as a feasible and attractive 
alternative for non-invasive delivery of potent peptide and protein drug molecules. 
However, the need for safe and effective buccal permeation/absorption enhancers is a 
crucial component for a prospective future in the area of buccal drug delivery (Nagai 
T, et.al., 1993). 
1.7.1FACTORS AFFECTING BUCCAL ABSORPTION 
The  oral  cavity is  a complex environment for drug  delivery  as  there are  
many  interdependent  and independent factors which reduce the absorbable 
concentration at the site of absorption. 
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1.7.1.1 Membrane Factors 
This involves degree of keratinization, surface area available for absorption, 
mucus layer of salivary pellicle,  intercellular lipids of epithelium, basement 
membrane and lamina propria. In addition, the absorptive membrane thickness,  blood 
supply/ lymph drainage, cell renewal and enzyme content will all contribute to 
reducing the rate and amount of drug entering the systemic circulation. 
1.7.1.2. Environmental Factors 
A. Saliva: The thin film of saliva coats throughout the lining of buccal mucosa and is 
called salivary pellicle or film. The thickness of salivary film is 0.07 to 0.10 mm. The 
thickness, composition and movement of this film affect the rate of buccal absorption. 
B. Salivary glands: The minor salivary glands are located in epithelial or deep 
epithelial region of buccal mucosa.  They constantly secrete mucus on surface of 
buccal mucosa.  Although, mucus helps to retain mucoadhesive dosage forms, it is 
potential barrier to drug penetration. 
C.Movement of buccal tissues: Buccal region of oral cavity shows less active 
movements. The mucoadhesive polymers are to be incorporated to keep dosage form 
at buccal region for long periods to withstand tissue movements during talking and if 
possible during eating food or swallowing. 
1.7.2 COMPOSITION OF BUCCAL PATCHES 
A.  Active ingredient. 
B. Polymers  (adhesive  layer):  Hydroxy  ethylcellulose,  hydroxypropyl  
cellulose,  polyvinyl  pyrrolidone, polyvinyl alcohol, carbopol and other 
mucoadhesive polymers. 
C. Diluents: Lactose DC is selected as diluent for its high aqueous solubility, its 
flavouring characteristics, and its  physico-mechanical properties, which make 
it suitable for direct compression. other example : microcrystalline starch and 
starch. 
D. Sweetening agents: Sucralose, aspartame, mannitol, etc. E.   Flavouring agents: 
Menthol, vanillin, clove oil, etc. 
F.   Backing layer: Ethyl cellulose, Aluminium foil etc. 
G.  Penetration enhancer: Cyano acrylate, etc. 
H.  Plasticizers: PEG-100, 400, propylene glycol, etc. 
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1.7.3 METHOD OF PREPARATION 
Two methods are used to prepare adhesive patches. 
1. Solvent casting 
2. Direct Milling 
1. Solvent Casting: 
In this method, all patch excipients including the drug co-dispersed in an organic 
solvent and coated onto a sheet of release liner. After solvent evaporation a thin layer 
of the protective backing material is laminated onto the sheet of coated  release liner 
to form a laminate that is die-cut to form patches of the desired size and geometry. 
2. Direct milling: 
In this, patches are manufactured without the use of solvents. Drug and excipients are 
mechanically mixed by direct milling or by kneading, usually without the presence of 
any liquids. After the mixing process, the resultant material is rolled on a release liner 
until the desired thickness is achieved. The backing material is then laminated as 
previously described. While there are only minor or even no differences in patch 
performance between patches fabricated by the two processes, the solvent-free 
process is preferred because there is no possibility of residual solvents and no 
associated solvent-related health issues. 
1.7.4 Advantages of Mucoadhesive Buccal Drug Delivery System 
Drugs administered via oral mucosa offers several advantages 
♦ Ease of administration. 
♦ Termination of therapy is easy. 
♦ Permits localization of drug to the oral cavity for a prolonged period of time. 
♦ Can be administered to unconscious patients. 
♦ Offers an excellent route, for the systemic delivery of drugs with high first 
pass metabolism, thereby offering a greater bioavailability. 
♦ A significant reduction in dose can be achieved there by reducing dose related 
side effects. 
♦ Drugs which are unstable in the acidic environment are destroyed by 
enzymatic or alkaline environment of intestine can be administered by this 
route. 
♦ Drugs which show poor bioavailability via the oral route can be administered 
conveniently. 
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♦ It offers a passive system of drug absorption and does not require any 
activation. 
♦ The presence of saliva ensures relatively large amount of water for drug 
dissolution unlike in case of rectal and transdermal routes. 
♦ Systemic absorption is rapid. 
♦ This route provides an alternative for the administration of various hormones, 
narcotic analgesic, steroids, enzymes, cardiovascular agents etc. 
♦ The Buccal mucosa is highly perfused with blood vessels and offers a greater 
permeability than the skin. 
 
1.7.5 Limitations of Buccal Drug Administration 
Drug administration via the buccal mucosa has certain limitations 
♦ Drugs, which irritate the oral mucosa, have a bitter or unpleasant taste, odor, 
cannot be administered by this route. 
♦ Drugs, which are unstable at buccal pH, cannot be administered by this route. 
♦ Only drugs with small dose requirements can be administered. 
♦ Drugs may swallow with saliva and loses the advantages of buccal route. 
♦ Only those drugs, which are absorbed by passive diffusion, can be 
administered by this route. 
♦ Eating and drinking may become restricted. 
♦ Swallowing of the formulation by the patient may be possible. 
♦ Over hydration may lead to the formation of slippery surface and structural 
integrity of the formulation may get disrupted by the swelling and hydration of 
the bioadhesive polymers. 
1.7.6 METHODS FOR MEASURING MUCOADHESION 
 These tests are important during the design and development of a 
mucoadhesive release system to study compatibility, stability, surface analysis and 
bioadhesive bond strength. These tests are broadly classified in to qualitative methods 
and quantitative methods. 
1.7.6.1 QUANTITATIVE METHODS:     
 These are also called macroscopic methods. The majority of the quantitative 
mucoadhesion measurement methods found in the literature is based on measuring the 
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force required to break the adhesive bond between the model membrane and the 
adhesive. 
a) Determination of peel strength: 
  The peel adhesion tests are mainly used for buccal and transdermal 
patches. The test is based on the calculation of energy required to detach the 
dosage form from the substrate material usually excised buccal mucosa attached 
through the bioadhesive material in the direction. 
Fracture Energy (G) 
 = w(1+k) 
Where P is the peel force and w is the peel width, W is the intrinsic work 
of adhesion and k is the proportionality constant that accounts for hysteretic 
losses. 
     b) Determination of shear strength: 
  Shear stress (τ) is the force acting tangentially to a surface divided by 
the area of the surface. It is the force per unit area required to sustain a constant 
rate of fluid movement. Mathematically, shear stress can be defined as: 
τ = F/A 
 τ shear stress, F force and A area of the surface subjected to the force. 
 There are three typical definitions of tensile strength: 
Yield strength: The stress that a material can withstand without permanent 
deformation. 
Ultimate strength: It is the maximum stress that a material can withstand. 
Breaking strength: The stress coordinate on the stress– strain curve at the point 
of rupture. 
  Methods using the tensile strength usually measure the force required 
to break the adhesive bond between a model membrane and the test polymers. 
     Colloidal gold staining method: 
  The technique employs red colloidal gold particles which were 
adsorbed on mucin molecules to form mucin–gold conjugates, which upon 
interaction with bioadhesive hydrogels develops a red color on the surface. This 
can be quantified by measuring at 525 nm either the intensity on the hydrogel 
surface or the conjugates. 
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Direct staining method 
  It is a novel technique to evaluate polymer adhesion to human buccal 
cells following exposure to aqueous polymer dispersion, both in-vitro and in-vivo. 
Adhering polymer was visualized by staining with 0.1% w/v of either Alcian blue 
or Eosin solution; and the uncomplexed dye is removed by washing with 0.25M 
sucrose. 
1.7.6.2 QUALITATIVE METHODS 
 These methods are useful for preliminary screening of the respective polymer 
for its bio or mucoadhesion, compatibility and stability. These methods are not useful 
in measuring the actual bioadhesive strength of the polymers. They are 
Viscometric method 
 Viscosities of 15% w/w porcine gastric mucin dispersion were measured with 
Brookfield's viscometer. In absence or presence of selected neutral, anionic and 
cationic polymer, viscosity components and the forces of bioadhesion are calculated 
Analytical ultracentrifuge criteria for mucoadhesion. 
 These methods are useful in identifying the material that is able to form 
complexes with the mucin. The assay can be done for change in molecular mass using 
sedimentation equilibrium, but this has an upper limit of less than 50MDa. UV 
absorption optics is used as the optical detection system. 
Atomic force microscopy 
 This method is based on the changes in surface topography when the polymer 
bound on to buccal cell surfaces. Unbound cells shows relatively smooth surface 
characteristics with many small craters like pits and indentations spread over cell 
surfaces; while polymer bound cells will lose crater and indentation characteristics 
and gained a higher surface roughness. 
Electrical conductance 
 Modified rotational viscometer is used to determine electrical conductance of 
various semi solid mucoadhesive ointments and found that the electrical conductance 
was low in the presence of adhesive material. 
1.7.6.3. Fluorescent probe method 
In this method the membrane lipid bilayered and membrane proteins were 
labelled with pyrene and fluorescein isothiocyanate, respectively. The cells were 
mixed with the mucoadhesive agents and changes in fluorescence spectra were 
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monitored. This gave a direct indication of polymer binding and its influence on 
polymer adhesion. 
Thumb test:  
This is a very simple test used for the qualitative determination of peel 
adhesive strength of the polymer and is useful tool in the development of buccal 
adhesive delivery systems. The adhesiveness is measured by the difficulty of pulling 
the thumb from the adhesive as a function of the pressure and the contact time. 
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2. LITERATURE REVIEW 
1) Pongjanyakul. T et.al., (2009), Developed a Sodium alginate-magnesium 
aluminum silicate (SA-MAS) dispersions with nicotine (NCT) were prepared at 
different pHs and characterized for the particle size and zeta potential, NCT adsorbed 
by MAS, and flow behavior before film casting. The physicochemical properties, 
NCT content, in vitro bioadhesive property study showed that incorporation of NCT 
into the SA-MAS dispersions caused a change in particle size and flow behavior and 
that NCT could be adsorbed by MAS. This finding suggests that the NCT-loaded SA-
MAS films composed of numerous NCT-MAS complexes as micro reservoirs 
demonstrated a strong potential for use as a buccal delivery system. 
2) Gavin P.A et.al. (2009), Studied the process of mucoadhesion involving a 
polymeric drug delivery platform is a complex one that includes wetting, adsorption 
and interpenetration of polymer chains amongst various other processes. The 
attractiveness of mucosal-targeted controlled drug delivery of active pharmaceutical 
ingredients (APIs), has led formulation scientists to engineer numerous polymeric 
systems for such tasks. Evolution of such mucoadhesive formulations has 
transgressed from first-generation charged hydrophilic polymer networks to more 
specific second-generation systems based on lectin, thiol and various other adhesive 
functional groups. 
 
3) Rajesh Singh. P et.al., (2009),   Had prepared Mucoadhesive patch releasing the 
drug in the oral cavity at predetermined rate may present distinct advantages over 
traditional dosage forms such as tablets, gels and solutions. The present study was 
concerned with the preparation and evaluation of mucoadhesive buccal patches for the 
controlled systemic delivery of Salbutamol sulphate to avoid first pass hepatic 
metabolism. The in-vitro release study showed that patches could deliver drug to the 
oral mucosa for a period of 7 h. the patches exhibited adequate stability when tested 
under accelerated conditions. 
 
4) Kharenko E. Aet.al, (2009),     His study addresses contemporary mucoadhesive 
drug delivery systems. The mucoadhesive interaction is explained in relation to the 
structural characteristics of mucosal tissues and the properties of the polymers. A 
separate section addresses the advantages and disadvantages of various mucoadhesive 
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drug delivery systems (tablets, films, gels, microcapsules, and nanocarriers) and 
developed and commercially available medicinal formulations based on 
mucoadhesive polymers. 
 
5) Alagusundaram M, et al., (2009),Have a wide scope of application for both 
systemic and local effects of drugs. The muco adhesive buccal films of ranitidine 
were prepared by solvent casting technique using polymers like hydroxy propyl 
methyl cellulose-15 cps and poly vinyl pyrrolidone. The best mucoadhesive 
performance and matrix controlled release was exhibited by the formulation R5 (2 % 
HPMC and 1 % PVP). The correlation coefficient value (r) indicates the kinetic of 
drug release was zero order. The formulation was found to be right and suitable 
candidate for the formulation of ranitidine buccal film for therapeutic use. 
6) Dinesh Dhamecha, et al., (2009), had formulated as floating drug delivery systems 
with an objective to sustain the release of drug in stomach. Ranitidine hydrochloride, 
formulated as floating matrix tablet using gas generating agent (sodium bicarbonate, 
citric acid) and polymers like HPMC K4M and polaxomer. Formulation was 
optimized on the basis of in vitro release. In vitro buoyancy was found to be in the 
range of 17 to 89 seconds and water uptake in the range of 125 to 280 %. Floating 
time was more than 24 hrs. In vitro drug release of the optimized batch was found to 
be 88% at the end of 8th hr. 
7) Ananta Choudhury, et al.,( 2009),has designed an extended release floating 
tablets of ranitidine hydrochloride and investigate the effect of formulation variables 
on drug release profile and floating property. Tablets were formulated using different 
concentration hydroxy propyl methyl cellulose K4M, carbopol 934 and sodium 
carboxy methyl cellulose .where Sodium bicarbonate and Citric acid used as a gas 
generating agent. It was observed that all the prepared formulation shows good 
floating capabilities up to 11 to 18 hours and slow steady release profile up to 12 
hours. 
8) Rajesh K, et al., (2009) had developed the preparation of ranitidine hydrochloride 
sustained release formulation for 24 hrs. Various formulations were prepared by wet 
granulation technique using the polymers, such as HPMC K100M and HPMC K15M. 
It was found that the best formulation for RT8 was having the floating lag time of 120 
sec and showed 98.4% drug release at the end of 24 hours. This way the best 
formulation was achieved by using the combination of high and low viscous polymers 
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HPMC K100M and HPMC K15M in the ratio of 1:1. In-vitro drug release studies of 
Ranitidine hydrochloride sustained release floating tablets showed that, the rate of 
drug release is diffusion controlled and follows zero order kinetics. 
9) Durga Jaiswal, et.al,(2009), had investigated to develop a multi-unit gastro 
retentive sustained release dosage form of a water soluble drug, Ranitidine 
hydrochloride, from a completely aqueous environment avoiding the use of any 
organic solvent, which could cure peptic ulcer more efficiently by releasing the drug 
especially in stomach and also for a prolonged duration of time. The results show that 
these beads can entrap even a water soluble drug as Ranitidine hydrochloride in 
sufficient amount and also can successfully deliver the drug in stomach for a prolong 
duration of time without using any organic solvent and any time consuming step in 
the preparation. 
10) Mastiholimath, et.al,(2008), had developed oral controlled release dosage forms, 
the formulated microspheres were free flowing with good pack ability and 
encapsulation efficiencies were up to 96%. Scanning electron microscopy confirmed 
porous, spherical particles in the size range 300–750 mm. Microspheres showed 
excellent buoyancy and a biphasic controlled release pattern with 12 h. In vivo 
bioavailability studies performed on rabbits and Tmax, Cmax, AUC were calculated 
and confirmed significant improvement in bioavailability. 
11)Yu-meng Wei, et al., (2008),had developed the hollow microspheres as a new 
dosage form of floating drug delivery systems with prolonged stomach retention time. 
The yield and drug loading amount of hollow microspheres were 83.21±0.28% and 
20.71±0.32%, respectively. Hollow microspheres could prolong drug release time 
(approximately 24 h) and float over the simulate gastric fluid for more than 24 h. 
These results demonstrated that RH hollow microspheres were capable of sustained 
delivery of the drug for longer period with increased bioavailability. 
12) Janardhan D, et al., (2008), had prepared gastro retentive drug delivery system 
of ranitidine hydrochloride. Six different gastro retentive tablets of ranitidine HCl 
were prepared by direct compression using different concentrations of Hydroxy 
propyl methyl cellulose (HPMC K4M), Carbopol, Sodium carboxy methyl cellulose, 
sodium bicarbonate and citric acid. In conclusion, effervescent is essential for the 
formulation to have good floating property and carbopol retards the drug release in 
floating formulations. floating behavior and drug content after storage at 40°C and 
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75% RH for three months showed no significant change by Student’s t-test indicating 
that formulation (HEC1) could provide a minimum shelf life of 2 years. 
13)Ehab R. et al., (2008),had research based on the hypothesis that leaky enteric-
coated pellets formulations are able to provide sustained input for drugs that have an 
absorption window, Eudragit-L30 D-55, combined with soluble compounds including 
lactose, PEG 8000 and surfactants (Span 60 (hydrophobic) or Tween 80 
(hydrophilic)). It also shows that enteric-coating polymers have new applications in 
areas other than the usual enteric-coated formulations. The hypothesis that a leaky 
enteric-coated pellets formulation may maintain or increase the bioavailability of 
drugs that have a window of absorption is still to be confirmed by further in vivo 
studies. 
14) Diaz Del Consuelo. I et.al., (2007),  Were designed a bioadhesive films for the 
buccal delivery of fentanyl, and to evaluate their performance in vitro using the pig 
esophageal model. Films were made with polyvinylpyrrolidone (PVP) of two 
different molecular weights: PVP K30 and PVP K90. Delivery of fentanyl was 
determined across full-thickness mucosa and across heat-separated epithelium (where 
the permeability barrier was shown to be located). The transport rates achieved rom 
the PVP films providing the highest delivery suggest that a buccal system of only 1–2 
cm2 in surface area could achieve a therapeutic effect equivalent to a 10 cm2 
transdermal patch, with a much shorter lag-time. 
15) Diaz Del Consuelo. I et.al, (2007),   were designed a bioadhesive films for the 
buccal delivery of fentanyl, and to evaluate their performance in vitro using the pig 
esophageal model. Films were made with polyvinylpyrrolidone (PVP) of two 
different molecular weights: PVP K30 and PVP K90. Delivery of fentanyl was 
determined across full-thickness mucosa and across heat-separated epithelium (where 
the permeability barrier was shown to be located). The transport rates achieved rom 
the PVP films providing the highest delivery suggest that a buccal system of only 1–2 
cm2 in surface area could achieve a therapeutic effect equivalent to a 10 cm2 
transdermal patch, with a much shorter lag-time. 
 
16) Donnelly. R. Fet.al, (2007), had designed a Mucocutaneous oropharyngeal 
candidiasis is predominately caused by Candida albicans. The current study, 
therefore, reports on a mucoadhesive patch containing toluidine blue O (TBO), as a 
potential delivery system for use in PACT of or pharyngeal candidiasis. When 
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releasing directly into an aqueous sink, patches containing 50 and 100 mg TBO cm_2 
both generated receiver compartment concentrations exceeding the concentration 
(2.0–5.0 mg ml_1) required to produce high levels of kill (>90%) of both planktonic 
and biofilm-grown C. albicans upon illumination. However, the concentrations of 
TBO in the receiver compartments separated from patches by membranes intended to 
mimic biofilm structures were an order of magnitude below those inducing high levels 
of kill, even after 6 h release. 
 
17) Dasharath M. et al., (2007), had developed and optimized a controlled-release 
multiunit floating system of a highly water soluble drug, ranitidine HCl, using 
Compritol, Gelucire 50/13, and Gelucire 43/01 as lipid carriers. Ranitidine HCl– lipid 
granules were prepared by the melt granulation technique and evaluated for in vitro 
floating and drug release. Batch F4 was considered optimum since it contained less 
Gelucire and was more similar to the theoretically predicted dissolution profile (f2 = 
62.43). These studies indicate that the hydrophobic lipid Gelucire 43/01 can be 
considered an effective carrier for design of a multiunit floating drug delivery system 
for highly water soluble drugs such as ranitidine HCl. 
 
18)Ameye. D et.al, (2005), had prepared, spray-dried Amioca® starch/Carbopol® 
974P mixtures were evaluated as potential buccal bioadhesive tablets. Carbopol® (C 
974P) concentrations from 5 to 75% were tested. All spray-dried mixtures showed a 
comparable or better bioadhesive capacity compared to a reference formulation 
(DDWM/C 974P 95/5). The mixtures containing between 15 and 30% C 974P could 
all sustain the in vitro miconazole nitrate release over 20h. Again, lower and higher C 
974P concentrations showed a faster in vitro miconazole release. The spray-dried 
mixture could be loaded with 60% drug without losing its in vivo bioadhesive and 
pharmacokinetic properties. 
 
19)Nazila S. M, et.al., (2005), Buccal delivery of the desired drug using 
mucoadhesive polymers has been the subject of interest since the early 1980s.. This 
review highlights the use of mucoadhesive polymers in buccal drug delivery. Starting 
with a review of the oral mucosa, mechanism of drug permeation, and characteristics 
of the desired polymers, this article then proceeds to cover the theories behind the 
adhesion of bioadhesive polymers to the mucosal epithelium. Additionally, we focus 
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on the new generation of mucoadhesive polymers such as thiolated polymers, 
followed by the recent mucoadhesive formulations for buccal drug delivery. 
 
20) Goud H. K et.al., (2004),  had prepared and evaluate a novel buccal adhesive 
system (NBAS) containing propranolol hydrochloride (PH). A special punch was 
fabricated and used while preparing an NBAS. NBASs containing carbopol (CP) 
934P and HPMC K4M at the ratio of 1:1 showed higher MS (44.76 g) with porcine 
buccal mucosa when compared with 1:2 (39.76 g), 0:1 (23.29 g), and 1:0 (22.22 g) 
ratios, respectively. It can be concluded that NBAS is a superior, novel system that 
overcomes the drawback associated with the conventional buccal adhesive tablet. 
 
21) Periolia. L et.al., (2004),  had designed a new formulation for topical 
administration of drugs in the oral cavity has been developed using several film-
forming and mucoadhesive polymers. The best film, containing polyvinylpyrrolidone 
(PVP) as film-forming polymer and carboxymethylcellulose sodium salt (NaCMC) as 
mucoadhesive polymer, was loaded with ibuprofen as a model compound and in vitro 
and in vivo release studies were performed. In vivo studies showed the presence of 
ibuprofen in saliva (range 70– 210 Ag/ml) for 5 h and no irritation was observed. 
 
22)Brijesh S. et al., (2004),had prepared a gastro retentive drug delivery system of 
ranitidine hydrochloride. The amounts of citric acid anhydrous (X1) and stearic acid 
(X2) were selected as independent variables. The times required for 50% (t50) and 
80% drug dissolution (t80), and the similarity factor f2 were selected as dependent 
variables. Batch F9 showed the highest f2 (f2 = 75) among all the batches, and this 
similarity is also reflected in t50 (~214 minutes) and t80 (~537 minutes) values. These 
studies indicate that the proper balance between a release rate enhancer and a release 
rate retardant can produce a drug dissolution profile similar to a theoretical dissolution 
profile. 
 
23)Nafee. N.A et.al., (2003), had prepared Mucoadhesive patches for delivery of 
cetylpyridinium chloride (CPC) were prepared using polyvinyl alcohol (PVA), 
hydroxyethyl cellulose (HEC) and chitosan. The results showed a remarkable increase 
in radial swelling (SD) after addition of the water-soluble drug (CPC) to the plain 
formulae. A decrease in the residence time was observed for PVA and chitosan-
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containing formulae. Higher drug release was obtained from PVA patches compared 
to HEC ones, while both are non-ionic polymers. Physical characteristics of the 
studied patches showed an increase in the residence time with storage accompanied 
with a decrease in drug release. 
 
24)Okamoto. H et.al., (2001), had formulated & examined the penetration rate of 
lidocaine (LC) through excised oral mucosa from hamster cheek pouch and the in 
vitro release rate of LC from film dosage forms with hydroxypropylcellulose (HPC) 
as a film base. A significant relationship between the penetration rate of LC and the 
release rate of unionized LC was found, suggesting that the in vitro dissolution study 
is useful tool to predict the penetration rate taking the unionized drug fraction into 
consideration. 
 
25)Amir H.S et.al., (2000), had designed based on the premise that similar surface 
properties between the adhesive and the substrate would yield a strong adhesive bond, 
copolymers of acrylic acid (AA) and 2-ethylhexyl acrylate (EHA), P(AA-co-EHA), 
were designed and synthesized for buccal mucoadhesion. The copolymer composed 
of 46:54 mol.% AA:EHA (an almost 1:1 ratio in the repeat units) yielded the highest 
mucoadhesive force in contact with porcine buccal mucosa which was significantly 
greater (P,0.05) than that of poly(acrylic acid) (PAA) (used as positive control). The 
mucoadhesive force for all copolymers studied was significantly (P, 0.05)   greater 
than that of the negative control (backing material without copolymer film) except for 
the EHA homopolymer. 
 
26) Fun Wong. C et.al, (1999), had prepared a controlled release buccal patches were 
fabricated using Eudragit NE40D and studied. Various bioadhesive polymers, namely 
hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose and Carbopol of 
different grades, were incorporated into the patches, to modify their bioadhesive 
properties as well as the rate of drug release, using metoprolol tartrate as the model 
drug. The in-vitro drug release was determined using the USP 23 dissolution test 
apparatus 5 with slight modification, while the bioadhesive properties were evaluated 
using texture analyzer Equipment with chicken pouch as the model tissue. Of the 
various bioadhesive polymers studied, Cekol 700 appeared to be most satisfactory in 
terms of modifying the drug release and enhancement of the bioadhesive properties. 
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27)Remunan-Lopez. C et.al, (1998), developed a new buccal bilayered devices 
comprising a drug-containing mucoadhesive layer and a drug-free backing layer, by 
two different methods. Bilaminated films were produced by a casting/solvent 
evaporation technique and bilayered tablets were obtained by direct compression. The 
bilaminated films showed a sustained drug release in a phosphate buffer (pH 6.4). 
Furthermore, tablets that displayed controlled swelling and drug release and adequate 
adhesivity were produced by in situ crosslinking the chitosan with polycarbophil. 
 
28) Burgalassi. S et.al, (1996), His studied concerned with the preparation and 
evaluation of mucoadhesive buccal patches for controlled release of benzydamine 
(BNZ) and lidocaine (LDC). The patches, prepared by compressing appropriate 
mixtures containing the drug salts/complexes, lactose and TG, were tested in vitro for 
mucoadhesion and drug release, and in vivo on human volunteers for retention and 
release of BNZ.. The patches adhered for over 8 h to the upper gums of the 
volunteers, and were perfectly tolerated. BNZ hydrochloride was released in vivo and 
in vitro with practically identical profiles. 
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3. AIM AND OBJECTIVE OF STUDY 
Lot of difficulties is involved in delivery of drugs via conventional routes. In 
the present study, the oral route, especially the buccal route was utilized as a platform 
for H2 receptor antagonist delivery. 
The main objective of this work was to formulate and evaluate Buccal Patches 
of CIMETIDINE. 
CIMETIDINE is a histamine H2-receptor antagonist.Histamine H2-antagonists 
inhibit the action of histamine on the acid-producing cells of the stomach and reduce 
stomach acid. 
Peroral administration of drugs has disadvantages such as hepatic first pass 
metabolism and enzymatic degradation within the GI tract therefore transmucosal 
routes of drug delivery (i.e., the mucosal linings of the nasal, rectal, vaginal, ocular, 
and oral cavity) are considered as potential sites for  systemic drug delivery as they 
have advantages which include bypass of first pass effect, avoidance of presystemic 
elimination within the GI tract, and, depending on the particular drug, a better 
enzymatic flora for drug absorption. 
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4.  PLAN OF WORK 
 
The experimental work consisted of 
1. Selection  and collection of raw materials 
2. Identification of the raw materials 
3. Casting of plain films with polymers. 
4. Preparation of drug incorporated polymeric films. 
5. Physicochemical evaluation of buccal films of Cimetidine. 
 Thickness. 
 Weight of films. 
 Folding endurance. 
6. Results 
7. Discussion 
8. Summary 
 
DISEASE PROFILE 
Department of Pharmaceutics Page 38 
5. DISEASE PROFILE 
Peptic ulcers are sores in the lining of the stomach or duodenum. Peptic ulcer 
formation is related to H.pylori bacteria in the stomach and non-steroidal anti-
inflammatory medications (NSAIDs) in 50% of patients. For the remaining 50% there 
are miscellaneous or unknown causes. 
Figure 6 – Peptic Ulcer. 
 
 
 
 
 
 
 
 
 
 
 
        
 
5.1 Causes: 
The following are the most important causes of peptic ulcers : 
• The most common cause is infection of the stomach with bacteria called 
Helicobacter pylori or H. pylori. This infection is quite common; about half of 
the world's population is infected. These bacteria cause the stomach to make 
too much acid, which damages the lining of the stomach or duodenum and can 
cause the ulcer. 
• Some medicines, called non-steroidal anti-inflammatory drugs (NSAIDs), can 
cause peptic ulcers. Examples of these medicines include aspirin, ibuprofen, 
naproxen and diclofenac. However most people can take these safely. If you 
are in doubt which painkillers to take, ask your pharmacist. 
• Smoking and drinking excessive alcohol increase your chances of developing 
a peptic ulcer. 
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     5.2 Symptoms of a peptic ulcer: 
• Abdominal pain, classically epigastric with severity relating to mealtimes, 
after around three hours of taking a meal. 
• Bloating and abdominal fullness. 
• Waterbrash (rush of saliva after an episode of regurgitation to dilute the acid 
in esophagus - although this is more associated with gastro esophageal reflux 
disease). 
• Nausea and copious vomiting. 
• Loss of appetite and weight loss. 
• Hematemesis (vomiting of blood); this can occur due to bleeding directly from 
a gastric ulcer, or from damage to the esophagus from severe/continuing 
vomiting. 
• Melena (tarry, foul-smelling feces due to oxidized iron from hemoglobin). 
• Rarely, an ulcer can lead to a gastric or duodenal perforation, which leads 
to acute peritonitis. This is extremely painful and requires immediate surgery. 
5.3 Treatment: 
Medications are usually used to treat mild-to-moderate ulcers. If the cause is 
bacterial, antibiotics can cure the ulcer. For recurrent, severe cases that do not respond 
to medication, surgery may be necessary. 
   Although alternative therapies have been shown to aid in the relief of 
symptoms, they should be used only as supplements to conventional treatment. You 
should not treat an ulcer on your own without first seeing your doctor. Over-the 
counter antacids and acid blockers may relieve some or all of the pain, but the relief is 
always short-lived. With a doctor's help, you can find relief from the ulcer pain, as 
well as a lifelong cure from the disease. Proton-pump inhibitor drugs such as Prilosec 
are the most cost-effective treatment options for peptic ulcers. The chief goals of 
treatment are reducing the amount of acid in the stomach, strengthening the protective 
linings that come in direct contact with gastric acids, and -- if your ulcer is caused by 
bacterial infection -- treating the H. pylori infection with medication. Your doctor will 
likely prescribe a combination of antibiotics, such as amoxicillin or tetracycline with 
metronidazole, along with Pepto-Bismol, proton-pump inhibitors, and/or histamine 
H2 blockers, all to be taken for 10-14 days. 
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   If these treatments are unsuccessful, or if you have developed serious 
complications as a result of your ulcer, surgery may be necessary. If your ulcer is 
hemorrhaging, the surgeon will identify the source of the bleeding (usually a small 
artery at the base of the ulcer) and repair it. Perforated ulcers -- holes in the entire 
stomach or duodenal wall -- must be surgically closed. This is an emergency 
procedure. 
   In some cases, a surgery to decrease stomach acid secretion may be necessary. 
However, peptic ulcer surgery is done only in emergency situations, because there are 
many potential complications associated with the procedure, including ulcer 
recurrence, liver complications, and ''dumping syndrome,'' which cause chronic 
abdominal pain, diarrhea, vomiting, and/or sweating after eating. 
CLASSIFICATION OF ANTIULCER DRUGS: 
1. Reduction of gastric acid: 
a) H2 Anti Histamines: Cimetidine, Ranitidine, Pantaprazole 
b) Proton Pump Inhibitors: Omeprazole, Lansoprazole, Pantoprazole, 
Rabeprazole 
c) Anti cholinergics: Pirenzapine, Propantheline, Oxyphenonium 
d) Prostaglandin Analogues: Misoprostil, Enprostil 
2) Neutralization of gastric acid: 
a) Systemic: Sodium bicarbonate(NaHCO3) 
b) Non-Systemic: Magnesium hydroxide, Magnesium trisilicate, 
Aluminum hydroxide gel 
3) Ulcer protective: Sucralfate, Colloidal bismuth sub citrate 
4) Ulcer Healing:  Carbenoxolone sodium 
5) Anti-H.pylori drugs: Amoxicillin, Clarithromycin, Metronidazole, 
Tinidazole, Tetracycline 
5.4 H2 RECEPTOR ANTAGONISTS 
 H2 blockers, also called H2-receptor antagonists, are medicines that reduce the 
amount of acid the stomach produces by blocking one important producer of acid: 
histamine 2. 
Histamine 2, a common chemical in the body, signals the stomach to make 
acid. H2 Blockers oppose histamines action and reduce the amount of acid the 
stomach produces. This type of medication is used to treat conditions in which the 
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stomach produces too much acid, such as gastroesophageal reflux disease. They also 
have been prescribed for the treatment of peptic ulcer symptoms. 
5.4.1 How Do H2 Blockers Work? 
 A cell in the stomach, called a parietal cell, makes acid. These cells, found in 
the stomach lining, are stimulated in a number of ways to produce acid. One of these 
methods is histamine. H2 Blockers reduce acid production by blocking signals that tell 
the stomach to make acid. 
 The H2 antagonists are competitive antagonists of histamine at the parietal 
cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the 
meal-stimulated secretion of acid. They accomplish this by two mechanisms: 
Histamine released by ECL cells in the stomach is blocked from binding on parietal 
cell H2 receptors, which stimulate acid secretion; therefore, other substances that 
promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on 
parietal cells when the H2 receptors are blocked. 
5.4.2 Mechanism of action: 
H2-RAs block histamine H2-receptors located in the parietal cell membrane 
and therefore directly and selectively reduce acid secretion from the parietal cells. If 
used at their recommended therapeutic doses, they reduce acid output by 50–60%; 
however, because acid secretion is also mediated through the gastrin and muscarinic 
receptors, substantial acid output is still observed. 
H2-RAs also partially decrease pepsin production through an unknown mechanism 
and reduce the volume of refluxate entering the oesophagus. They have no effect on 
LOS activity, oesophageal clearance or gastric emptying. 
5.4.3 Efficacy: 
H2-RAs generally relieve reflux symptoms in approximately 50% of patients 
with GORD, although their efficacy in healing oesophagitis is less clear and 
dependent on the severity of oesophagitis, they are more effective in less severe 
oesophagitis. 
The primary indication for H2-RAs, however, is peptic ulceration. In this 
indication, all of the products produce symptomatic relief in 1–2 weeks, and 75% of 
ulcers are healed by a 4–8 week course. However, relapse is common, and 60–80% of 
patients may relapse within 1 year if not given maintenance treatment. 
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6. DRUG PROFILE 
Cimetidine is a competitive inhibitor of histamine H2-receptors, used as an anti 
ulcerative agent. 
6.1 Chemical Formula 
C13H22N4O3S 
6.2 Structure 
 
 
 
 
 
6.3 Chemical Name 
N-cyano-N [2-[[[5-[(dimethylamino) methyl]-2-furanyl] methyl] thio] ethyl]-
N'-methyl-2-nitro-1, 1-ethenediamine. 
6.4 Molecular Weight 
350.87. 
6.5 Description 
Cimetidine is a colorless crystalline solid, slightly soluble in water. 
6.6 Solubulity 
Hydrochloride salt is highly soluble in water. 
6.7 Pharmacokinetics 
6.7.1 Absorption 
Cimetidine is 60 % absorbed after oral administration, compared to an 
intravenous (IV) injection with mean peak levels of 200 to 300ng/ml occurring 1 to 2 
hours after a 200 mg dose. Absorption is not significantly impaired by the 
administration of food or antacids. Propantheline slightly delays and increases peak 
blood levels of cimetidine, probably by delaying gastric emptying and transit time. In 
one study, simultaneous administration of high-potency antacid (150 mmol) in fasting 
subjects has been reported to decrease the absorption of cimetidine. 
6.7.2 Distribution 
The volume of distribution is about 1.2 L/kg. Serum protei binding averages 
15 %. 
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6.7.3 Metabolism 
In humans, the N-oxide is the principal metabolite in the urine; however, this 
amounts to <4 % of the dose. Other metabolites are the S-oxide (1 %) and the 
desmethyl ranitidine (1 %). The remainder of the administered dose is found in the 
stool. Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate 
that there are minor, but clinically insignificant, alterations in cimetidine half-life, 
distribution, clearance, and bioavailability. 
6.7.4 Excretion 
The principal route of excretion is the urine, with approximately 30 % of the 
orally administered dose collected in the urine as unchanged drug in 24 hours. Renal 
clearance is about 420 ml/min, indicating active tubular excretion. The elimination 
half-life is 2 to 3 hours. Four patients with clinically significant renal function 
impairment (creatinine clearance 25 to 35 ml/min) administered 50 mg of cimetidine 
intravenously had an average plasma half-life of 4.5 hours, a ranitidine clearance of 
29 mL./min, and a volume of distribution of 1.76 L/kg. In general, these parameters 
appear to be altered in proportion to creatinine clearance. 
6.8 Pharmacodyanamics  
Serum concentrations necessary to inhibit 50 % of stimulated gastric acid 
secretion are estimated to be 50 to 90 ng/mL. Following a single oral dose of 200 mg, 
serum concentrations of cimetidine are in this range up to 12 hours. However, blood 
levels bear no consistent relationship to dose or degree of acid inhibition. In a 
pharmacodynamic comparison of the EFFER dose with the cimetidine Tablets, during 
the first hour after administration, the EFFER dose tablet formulation gave a 
significantly higher intragastric pH, by approximately 1 pH unit, compared to the 
cimetidine tablets. Whose gastric ulcers had been previously healed, cimetidine 200 
mg was significantly more effective than placebo in maintaining healing of gastric 
ulcers. 
6.9 Clinical Pharmacology 
Cimetidine is a competitive, reversible inhibitor of the action of histamine at 
the histamine H2 receptors, including receptors on the gastric cells. Cimetidine does 
not lower serum Ca2+ in hypercalcemic states. Cimetidine is not an anti cholinergic 
agent. 
6.10 Indications and Usage for Cimetidine 
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Cimetidine is indicated in: 
1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 
weeks. Studies available to date have not assessed the safety of Cimetidine in 
uncomplicated duodenal ulcer for periods of more than 8 weeks. 
2) Maintenance therapy for duodenal ulcer patients at reduced dosage after 
healing of acute ulcers. No placebo-controlled comparative studies have been 
carried out for periods of longer than 1 year. 
3) The treatment of pathological hypersecretory conditions (e.g., Zollinger-
Ellison syndrome and systemic mastocytosis). 
4) Short-term treatment of active, benign gastric ulcer. Most patients heal within 
6 weeks and the usefulness of further treatment has not been demonstrated. 
Studies available to date have not assessed the safety of Cimetidine in 
uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 
5) Maintenance therapy for gastric ulcer patients at reduced dosage after healing 
of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 
6) Treatment of gastro esophageal reflux disease (GERD). Symptomatic relief 
commonly occurs within 24 hours after starting therapy with Cimetidine 200 
mg b.i.d. 
7) Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic 
relief of heartburn commonly occurs within 24 hours of therapy initiation with 
Cimetidine 200 mg q.i.d. 
8) Maintenance of healing of erosive esophagitis. Placebo-controlled trials have 
been carried out for 48 weeks. 
9) Concomitant antacids should be given as needed for pain relief to patients with 
active duodenal ulcer, active benign gastric ulcer, hypersecretory states, 
GERD and erosive esophagitis. 
6.11 Contraindications 
Hypersensitivity to any component of these products. Cross sensitivity in this 
class of compounds has been observed. Therefore, Cimetidine should not be 
administered to patients with a history of hypersensitivity to other H2-receptor 
antagonists. 
6.12 Drug Interactions 
Cimetidine has been reported to bind weakly to cytochrome P-450 in vitro, 
recommended doses of the drug slightly inhibit the action of the cytochrome P-450-
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linked oxygenase enzymes in the liver. Increased or decreased prothrombin times 
have been reported during concurrent use of Cimetidine and warfarin. 
In a Cimetidine -triazolam drug-drug interaction study, triazolam plasma 
concentrations were higher during b.i.d. dosing of Cimetidine than triazolam given 
alone. The clinical significance of this triazolam and Cimetidine pharmacokinetic 
interaction is unknown. 
6.13 Side Effects 
The following have been reported as events in clinical trials or in the routine 
management of patients treated with Cimetidine. The relationship to therapy with 
Cimetidine has been unclear in many cases. Headache, sometimes severe, seems to be 
related to administration of Cimetidine. 
6.13.1 Central Nervous System 
Rarely, malaise, dizziness, somnolence, insomnia, and vertigo. Rare cases of 
reversible mental confusion, agitation, depression, and hallucinations have been 
reported, predominantly in severely ill elderly patients. Rare cases of reversible 
blurred vision suggestive of a change in accommodation have been reported. Rare 
reports of reversible involuntary motor disturbances have been received. 
6.13.2 Cardiovascular 
As with other H2-blockers, rare reports of arrhythmias such as tachycardia, 
bradycardia, atrioventricular block, and premature ventricular beats. 
6.13.3 Gastrointestinal 
Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, and rare 
reports of pancreatitis. 
6.13.4 Hepatic 
There have been occasional reports of hepatocellular, cholestatic, or mixed 
hepatitis, with or without jaundice. In such circumstances, Cimetidine should be 
immediately discontinued. These events are usually reversible, but in rare 
circumstances death has occurred. Rare cases of hepatic failure have also been 
reported. In normal volunteers, SGPT values were increased to at least twice the 
pretreatment levels in 6 of 12 subjects receiving 100 mg q.i.d. intravenously for 7 
days, and in 4 of 24 subjects receiving 50 mg q.i.d. intravenously for 5 days. 
6.13.5 Musculoskeletal 
Rare reports of Arthralgia and myalgias. 
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6.13.6 Hematologic 
Blood count changes (leukopenia, granulocytopenia, and thrombocytopenia) 
have occurred in a few patients. These were usually reversible. Rare cases of 
agranulocytosis, pancytopenia, sometimes with marrow hypoplasia, and aplastic 
anemia and exceedingly rare cases of acquiredimmunehemolyticanemia have been 
reported. 
6.13.7 Endocrine 
Controlled studies in animals and man have shown cimetidine induced 
gynecomastia and impotence in hypersecretory patients. However, occasional cases of 
gynecomastia, impotence, and loss of libido have been reported in male patients 
receiving Ranitidine, but the incidence did not differ from that in the general 
population. 
6.13.8 Integumentary 
Rash, including rare cases of erythema multiform. Rare cases of alopecia and 
vasculitis. 
6.13.9 Respiratory 
A large epidemiological study suggested an increased risk of developing 
pneumonia in current users of histamine-2-receptor antagonists (H2RAs) compared to 
patients who had stopped H2RA treatment, with an observed adjusted relative risk of 
1.63 (95  % CI, 1.07-2.48). However, a causal relationship between use of H2RAs and 
pneumonia has not been established. 
6.13.10 Other 
Rare cases of hypersensitivity reactions (e.g., bronchospasm, fever, rash, 
eosinophilia), anaphylaxis, angioneurotic edema, and small increases in serum 
creatinine. 
6.14 Dosage and Administration 
6.14.1 Duodenal Ulcer 
The current recommended adult oral dosage of Cimetidine for duodenal ulcer 
is 200 mg twice daily. An alternative dosage of 400 mg once daily after the evening 
meal or at bedtime can be used for patients in whom dosing convenience is important. 
Smaller doses have been shown to be equally effective in inhibiting gastric acid 
secretion in US studies, and several foreign trials have shown that 100 mg twice daily 
is as effective as the 200 mg dose. 
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6.14.2 Benign Gastric Ulcer 
The current recommended adult oral dosage is 200 mg twice a day. 
6.14.3 Pathological Hypersecretory Conditions (such as Zollinger-Ellison 
syndrome) 
The current recommended adult oral dosage is 200 mg twice a day. In some 
patients it may be necessary to administer. Cimetidine 200 mg doses more frequently. 
Dosages should be adjusted to individual patient needs, and should continue as long 
as clinically indicated. Dosages up to 6 g/day have been employed in patients with 
severe disease. 
6.14.4 Gastro esophageal Reflux Disease (GERD) 
The current recommended adult oral dosage is 200 mg twice a day. 
6.14.5 Erosive Esophagitis  
The current recommended adult oral dosage is 200 mg 4 times a day. 
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7. EXCIPIENT PROFILE 
7.1 HYDROXY PROPYL METHYL CELLULOSE(15CPS) 
7.1.1 Nonproprietary Names 
• BP: Hypromellose 
• Ph Euro:  Methylhydroxypropylcellulosum 
• USP: Hydroxypropyl methylcellulose. 
7.1.2 Synonyms 
Cellulose, Hydroxypropyl methyl ether, Methocel; Methylcellulose propylene 
glycol ether; methyl Hydroxypropyl cellulose; Metolose; Pharmacoat. 
7.1.3 Functional Category 
Coating agent; film-former; stabilizing agent; suspending agent; tablet binder 
(2-5 %); viscosity-increasing agent, thickening agent (0.45-1 %). 
7.1.4 Molecular Weight 
10,000-1, 50,000 
7.1.5 Structure 
 
 
 
 
R is H, CH3 or [CH3 CH (OH) CH2] 
 
7.1.6 Solubility 
Soluble in cold water certain grades of HPMC are soluble in aqueous acetone 
solution, mixture of dichloromethane and propen-2-ol and other organic solvents. 
7.1.7 Stability and Storage Condition 
Very stable in dry conditions solution stable in pH 3.0 to pH 11. 
7.1.8 Applications 
1. In Oral and Topical pharmaceutical formulations. In oral products, hydroxy 
propyl methylcellulose is primarily used as a tablet binder, in film coating and as 
an extended release tablet matrix. Concentrations of between 2.5 % w/w may be 
used as a binder in either wet or dry granulation processes. 
2. High viscosity grades may be used to retard the release of water-soluble drugs 
from a matrix. 
O
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3. 2-10 % w/w is used as film-forming solutions to film-coat tablets. Lower 
viscosity grades are used with organic solvents. 
4. It is used as suspending and thickening agent in topical formulations, particularly 
in ophthalmic preparations. 
5. 0.45 %-1.0 %w/w may be added as thickening agent to vehicles for eye-drops 
and artificial tear solutions. 
6. It is an emulsifier. Suspending agent and stabilizing agent in topical gels and 
ointments. 
7. Used as an adhesive in plastic bandages and as a wetting agent for contact lenses. 
8. It is widely used in cosmetics and food products. 
7.1.9 Description 
Hydroxy propyl methylcellulose is an odorless and tasteless. White or creamy-
white colored fibrous or granular powder. 
7.1.10 Stability and Storage 
It is a stable material although it is hygroscopic after drying. It should be 
stored in airtight container, in a cool, dry place. 
 
7.1.11 Incompatibilities 
 It is incompatible with oxidizing agents. Since it is nonionic, it will not 
complex with metallic salts and ionic organics to form insoluble precipitates. 
7.2 SODIUMCARBOXY METHYL CELLULOSE (SCMC) 
7.2.1 Nonproprietary Name 
BP: Carmellose sodium 
JP: Carmellose sodium 
PhEur: Carmellosum natricum 
USP: Carboxymethylcellulose sodium 
7.2.2 Synonyms 
 Akucell; Aquasorb; Blanose; cellulose gum; CMC sodium; E466; Finnfix; 
Nymcel; SCMC; sodium carboxy methyl cellulose; sodium cellulose glycolate; 
sodium CMC; Tylose CB. 
7.2.3 Chemical Name and CAS Registry Number 
 Cellulose, carboxy methyl ether, sodium salt [9004-32-4] 
7.2.4 Empirical Formula and Molecular Weight 
The USP 28 describes carboxy methylcellulose sodium as the sodium salt of poly 
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carboxy methyl ether of cellulose. Typical molecular weight is 90 000–700 000. 
7.2.5 Structural Formula 
 
 
 
 
 
 
 
7.2.6 Functional Category 
 Coating agent; stabilizing agent; suspending agent; tablet and capsule 
disintegrant; tablet binder; viscosity-increasing agent; water-absorbing agent. 
7.2.7 Applications in Pharmaceutical Formulation or Technology 
 Carboxymethylcellulose sodium is widely used in oral and topical 
pharmaceutical formulations, primarily for its viscosity increasing properties. Viscous 
aqueous solutions are used to suspend powders intended for either topical application 
or oral and parenteral administration. Carboxymethylcellulose sodium may also be 
used as a tablet binder and disintegrant, and to stabilize emulsions. Higher 
concentrations, usually 3–6%, of the medium viscosity grade are used to produce gels 
that can be used as the base for applications and pastes; glycols are often included in 
such gels to prevent them drying out. Carboxymethylcellulose sodium is additionally 
one of the main ingredients of self adhesive ostomy, wound care, and dermatological 
patches, where it is used as a muco-adhesive and to absorb wound exudates or Trans 
epidermal water and sweat. This mucoadhesive property is used in products designed 
to prevent post-surgical tissue adhesions; and to localize and modify the release 
kinetics of active ingredients applied to mucous membranes; and for bone repair. 
Encapsulation with carboxy methylcellulose Sodium can affect drug protection and 
delivery. There have also been reports of its use as a cyto protective agent. 
Carboxymethylcellulose sodium is also used in cosmetics, Toiletries, surgical 
prosthetics and incontinence, personal hygiene, and food products. 
7.2.8 Description 
 Carboxymethylcellulose sodium occurs as a white to almost white, odorless, 
granular powder. 
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7.2.9 Typical Properties 
Density (bulk): 0.52 g/cm3 
Density (tapped): 0.78 g/cm3 
Dissociation constant: pKa = 4.30 
Melting point: browns at approximately 227ºC, and chars at approximately 252ºC. 
Moisture content: Typically contains less than 10% water. However, carboxy 
methylcellulose sodium is hygroscopic and absorbs significant amounts of water at 
temperatures up to 378C at relative humidities of about 80%. 
7.2.10 Solubility 
 Practically insoluble in acetone, ethanol (95%), ether, and toluene. Easily 
dispersed in water at all temperatures, forming clear, colloidal solutions. The aqueous 
solubility varies with the degree of substitution (DS). 
7.2.11 Viscosity 
 Various grades of carboxy methylcellulose sodium are commercially available 
that have differing aqueous viscosities; viscosities of 5–13 000 mPa s (5–13 000 cP) 
may be obtained. An increase in concentration results in an increase in aqueous 
solution viscosity. Prolonged heating at high temperatures will depolymerize the gum 
and permanently decrease the viscosity. The viscosity of sodium carboxy 
methylcellulose 
Solutions are fairly stable over a pH range of 4–10. The optimum pH range is 
neutral. 
Low viscosity Akucell AF 0305 10–15 #1 60 rpm 
Medium viscosity Akucell AF 2785 1500–2500 #3 30 rpm 
High viscosity Akucell AF 3085 8000–12000 #4 30 rpm 
7.2.12 Stability and Storage Conditions 
 Carboxymethylcellulose sodium is a stable, though hygroscopic material. 
Under high-humidity conditions, carboxy methylcellulose sodium can absorb a large 
quantity (>50%) of water. Carboxymethylcellulose Sodium 121 in tablets, this has 
been associated with a decrease in tablet hardness and an increase in disintegration 
time. Aqueous solutions are stable at pH 2–10; precipitation can occur below pH 2, 
and solution viscosity decreases rapidly above pH 10. Generally, solutions exhibit 
maximum viscosity and stability at pH 7–9. Carboxymethylcellulose sodium may be 
sterilized in the dry state by maintaining it at a temperature of 1608C for 1 hour. The 
bulk material should be stored in a well-closed container in a cool, dry place. 
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7.3 POLYVINYL ALCOHOL (PVA) 
7.3.1 Nonproprietary Names: 
• PhEur: Poly(vinylis acetas) 
• USP: Polyvinyl alcohol 
7.3.2 Synonyms: 
Airvol; Alcotex; Elvanol; Gelvatol; Gohsenol; Lemol; Mowiol; Polyvinol; 
PVA; vinyl alcohol polymer. 
7.3.3 Chemical Names and CAS Registry Number: 
Ethanol, homopolymer [9002-89-5] 
7.3.4 Empirical Formula and Molecular Weight: 
(C2H4O) n 20 000–200 000 
Polyvinyl alcohol is a water-soluble synthetic polymer represented by the 
formula (C2H4O)n. The value of n for commercially available materials lies between 
500 and 5000, equivalent to a molecular weight range of approximately 20 000–200 
000, 
Table 4:Commercially available grades of polyvinyl alcohol. 
Grade Molecular weight 
High viscosity 200 000 
Medium viscosity 130 000 
Low viscosity 130 000 
7.3.5 Structural Formula: 
 
 
 
 
7.3.6 Functional Category: 
Coating agent; lubricant; stabilizing agent; viscosity-increasing agent. 
7.3.7 Applications in Pharmaceutical Formulation or Technology 
• Polyvinyl alcohol is used primarily in topical pharmaceutical and ophthalmic 
formulations; 
• Is used as a stabilizing agent for emulsions (0.25–3.0% w/v). 
• As a viscosity-increasing agent for viscous formulations such as ophthalmic 
products. 
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• It is used in artificial tears and contact lens solutions for lubrication purposes, 
• In sustained-release formulations for oral administration and in transdermal 
patches. 
• Polyvinyl alcohol may be made into microspheres when mixed with a 
glutaraldehyde solution. 
7.3.8 Description: 
Polyvinyl alcohol occurs as an odorless, white to cream-colored granular 
powder. 
7.3.9 Pharmacopeial Specifications: 
Table 5:Pharmacopeial specifications for polyvinyl alcohol. 
Ph 4.5–6.5 5.0–8.0 
Loss on drying 45.0% 45.0 
Residue on ignition 41.0% 42.0% 
Water-soluble substances 40.1% 
Degree of hydrolysis 40.1% 
Assay 85.0–115.0% 
Test PhEur 2005 USP 28 
7.3.10 Typical Properties 
Melting point:  228ºC for fully hydrolyzed grades; 180–190ºC for partially 
hydrolyzed grades. 
Refractive index: nD 25 = 1.49–1.53 
Solubility: soluble in water; slightly soluble in ethanol (95%); insoluble in 
organic solvents. Dissolution requires dispersion (wetting) of the solid in water at 
room temperature followed by heating the mixture to about 908C for approximately 5 
minutes. Mixing should be continued while the heated solution is cooled to room 
temperature. 
Specific gravity: 1.19–1.31 for solid at 258C; 1.02 for 10% w/v aqueous solution at 
25C. 
Specific heat: 1.67 J/g (0.4 cal/g) 
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Table 6: Viscosity of commercial grades of polyvinyl alcohol. 
 
 
 
 
 
Grade Dynamic viscosity of 4% w/v aqueous solution at 208C (mPa s) 
7.3.11 Stability and Storage Conditions 
Polyvinyl alcohol is stable when stored in a tightly sealed container in a cool, 
dry place. Aqueous solutions are stable in corrosion-resistant sealed containers. 
Preservatives may be added to the solution if extended storage is required. Polyvinyl 
alcohol undergoes slow degradation at 100ºC and rapid degradation at 200ºC; it is 
stable on exposure to light. 
7.3.12 Incompatibilities 
Polyvinyl alcohol undergoes reactions typical of a compound with secondary hydroxy 
groups, such as esterification. It decomposes in strong acids, and softens or dissolves 
in weak acids and alkalis. It is incompatible at high concentration with inorganic salts, 
especially sulfates and phosphates; precipitation of polyvinyl alcohol 5% w/v can be 
caused by phosphates. Gelling of polyvinyl alcohol solution may occur if borax is 
present. 
7.3.13 Safety 
Polyvinyl alcohol is generally considered a nontoxic material. It is nonirritant 
to the skin and eyes at concentrations up to 10%; concentrations up to 7% are used in 
cosmetics. 
Studies in rats have shown that polyvinyl alcohol 5% w/v aqueous solution 
injected subcutaneously can cause anemia and infiltrate various organs and tissues. 
LD50 (mouse, oral): 14.7 g/kg, LD50 (rat, oral): >20 g/kg 
7.4SUITABILITY OF DRUG 
• Cimetidine is a competitive inhibitor of selective histamine H2 receptor 
antagonist, used as an antiulcerative agent and it is a drug of choice in the 
treatment of gastric ulcer and readily absorbed from gastro intestinal tract. 
High viscosity 
40.0–65.0 
 
Medium viscosity 
21.0–33.0 
 
Low viscosity 
4.0–7.0 
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• The bioavailability of Cimetidine following oral administration is about 60 % 
which might be due to colonic degradation by colonic bacteria. So with buccal 
drug delivery the bioavailability may increases by avoiding the colonic 
degradation. i.e. the bioavailability of Cimetidine is markedly lower from the 
human colon than the upper part of GI tract. 
• Cimetidine undergoes minimal first pass metabolism. After oral administration    
60 % absorbed when compared to an intravenous injection with mean peak 
levels occurring 1 to 2 hours. But in case of buccal film the peak plasma level 
of drug occur in more than 10 h and the therapy has to be maintained. 
• By entrapment of drug in the form of buccal film, the dose could be 
minimized. 
• By considering the above mentioned points the ranitidine might be right and 
suitable candidate for the formulation of mucoadhesive buccal film. 
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8. MATERIALS & INSTRUMENTS USED 
 
8.1 MATERIALS USED: 
Table 07- Materials Used 
 
8.2 INSTRUMENTS USED: 
Table 08- Instruments Used 
 
S.NO. Materials Suppliers/Manufacturers 
1 Cimetidine Drugs India, Hyderabad 
2 Phosphate buffer ---------------- 
3 Hydroxy propyl methyl cellulose Drugs India, Hyderabad 
4 Poly vinyl alcohol Drugs India, Hyderabad 
5 Ethanol Golden scientific, Thanjavur 
6 Sodium carboxy methyl 
cellulose Drugs India, Hyderabad 
7 Glycerol Karnataka fine chem. Industries, Bangalore 
S.NO. Instruments Suppliers/Manufacturers 
1 Glass Plates Borosil 
2 ‘O’ shaped rings 
 
3 Petri Dishes Rajas Enterprises (India) 
4 Open ended cylinder 
 
5 Digital Balance ShimadzuAX-200 corporation, 
Japan 
6 UV Spectrophotometer UV-1700Shimadzu corporation, 
Japan 
7 Magnetic Stirrer Remi,India 
8 FTIR Lab India,Spectrum RXI 
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9. PREFORMULATION STUDIES 
Before formulation of drug substances in to a dosage forms, Preformulation 
studies give the information needed to define the nature of drug substances and 
provide a frame work for the drug combination with pharmaceutical excipients in the 
fabrication of dosage form. 
Preformulation studies relate to pharmaceutical and analytical investigation 
carried out in supporting formulation development efforts of the dosage form 
The following preformulation studies were performed for the obtained sample 
of the drug. 
9.1. Organoleptic Properties 
9.1.1 Color and Nature: 
Transferred small quantity of the sample on a white piece of paper,spreaded 
the powder and examined visually. 
9.1.2 Taste and Odour: 
Very less quantity of Cimetidine was used to get taste with the help of tongue 
as well as smelled to get the odour. 
9.2 Melting Point: 
It is one of the parameters to judge the purity of crude drugs.  In case of pure 
chemicals, melting points are very sharp and constant. 
       Procedure: 
         Small quantity of Cimetidine to be examined is dissolved in 2-propanol R. It is 
evaporated to dryness and the melting point is determined.  
9.3 Solubility: 
       A semi quantitative determination of the solubility was made by adding 
solvent in small incremental amount to a test tube containing fixed quantity of solute 
or vice versa.  After each addition, the system is vigorously shaken and examined 
visually for any undissolved solute particles.   The solubility is expressed in terms of 
ratio of solute and solvent. 
9.4. STANDARDISATION OF STANDARD CURVE FOR CIMETIDINE 
An accurately weighed 100 mg of Cimetidine was dissolved in pH 6.8 
phosphate buffer as per I.P and make up the volume up to 100 ml in a volumetric 
flask, (Stock Solution: I, 1000 µg/ml) . From this 5 ml of solution were pipette out 
and make up the volume up to 100 ml (Stock Solution: II, 50µg/ml). Then the aliquots 
were prepared, whose concentration ranging from 2 to 20 µg/ml and the absorbance 
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were measured at 313 nm at UV Spectrophotometer Labomed, (Model No: 2602) 
against the reagent blank. 
                         
                 TABLE NO. 9: Values for the Standardisation of Cimetidine 
CONCENTRATION 
IN µg/ml 
ABSORBANCE AT 
313 nm 
0 0 
2 0.033 
4 0.049 
6 0.082 
8 0.103 
10 0.129 
12 0.152 
14 0.174 
16 0.203 
18 0.222 
20 0.243 
 
Figure 7 - Caliberation Curve of Cimetidine at pH-6.8 
 
 
9.5.Drug-excipient compatibility studies: 
 Drug-excipient compatibility studies are important to know the interaction 
between drug and excipients and in between excipients of the formulation, which 
could later affect the stability of the formulation and may interfere with the 
pharmacological action of the drug. 
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The physical examination of the formulation is done when alone and in 
combination with the excipients. If there is any change in the physical appearance, 
shows that there is interaction. 
 But some substances do not show any physical changes when combined in a 
formulation, for such FT-IR (Fourier transform-infrared) studies are conducted. 
 
Procedure by FT-IR studies: 
The FT-IR studies are conducted for metformin and mixture of metformin and 
excipients by preparing dispersion in potassium bromide discs. The peaks are 
obtained and compared with the standards by superimposing these spectra and 
observed for any difference in shape and size of spectrum. If there is any significant 
change represents interaction between drug and excipients.  
The drug Cimetidine, Hydroxy propyl methyl cellulose, sodium carboxy 
methyl cellulose and polyvinyl alcohol  compatibility and their functional integrity 
were confirmed through FTIR spectroscopy study as a preliminary confirmation 
recorded on a FTIR model-2500 apparatus using KBR disc  in the range of 4000–400 
cm–1 by applying 5.5 metric tons of pressure for preparing disc.  
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10. FORMULATION 
 10.1   FABRICATION OF DRUG FREE BUCCAL FILMS 
The films were prepared by the method of solvent casting technique 
employing ‘O’ shape ring placed on a glass surface as substrate or on Petridish. 
The calculated quantities of polymers Hydroxy Propyl Methyl Cellulose - 15 
cps (HPMC), sodium carboxy methyl cellulose (scmc), were dispersed in water and 
ethanol. Poly Vinyl Alcohol (PVA) solution is prepared by using, PVA powder 0.5% 
(w/v) was dissolved in hot water at 80 to 100 °C, and then glycerol was added under 
stirring. The polymeric solutions are levigation with specified amount of glycerol 
which served the purpose of plasticizer as well as penetration enhancer. The solution 
was mixed occasionally to get semisolid consistency. Then this were casted on a 
petridish having 2cm in diameter is covered with funnel to controlling the evaporation 
of solvent  and allowed to dry at room temperature over night or up to its dry. The 
dried films were separated and the backing membrane used was aluminium foil. Then 
the formulations were stored in a desiccator until further use. 
 
10.2 FABRICATION OF CIMETIDINE BUCCAL FILMS 
The films were prepared by the method of solvent casting technique 
employing ‘O’ shape ring placed on a glass surface as substrate or on petridish 
The calculated quantities of polymers Hydroxy Propyl Methyl Cellulose - 15 
cps (HPMC), sodium carboxy methyl cellulose (SCMC), were dispersed in water and 
ethanol. Poly Vinyl alcohol (PVA) solution is prepared by using, PVA powder 0.5% 
(m/v) was dissolved in hot water at 80 to 100 °C, and then glycerol was added under 
stirring. An accurately weighed 100 mg Cimetidine was incorporated in polymeric 
solutions after levigation with specified amount of glycerol which served the purpose 
of plasticizer as well as penetration enhancer. The solution was mixed occasionally to 
get semisolid consistency. The solution was mixed occasionally to get semisolid 
consistency. Then this were casted on a petridish having 2cm in diameter is covered 
with funnel to controlling the evaporation of solvent  and allowed to dry at room 
temperature over night or up to its dry. The dried films were separated and the 
backing membrane used was aluminium foil. Then the formulations were stored in a 
desiccator until further use. 
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TABLE NO. 10: The Composition of Patches Prepared Using Cimetidine 
Batch 
code 
Drug in 
mg 
Polymer in % Plasticizer 
HPMC SCMC PVP Glycerol 
F1 100 2 - -- 0.5 
F2 100 - 2 -- 0.5 
F3 100 1.5 0.5 - 0.5 
F4 100 0.5 1.5 - 0.5 
F5 100 1.5 - 0.5 0.5 
F6 100 - 1.5 0.5 0.5 
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11. EVALUATION 
11.1. THICKNESS 
The thickness of the each film was measured by using a digital vernier caliper 
at six different positions of the film and the average thickness was calculated. 
11.2. WEIGHT OF FILMS  
The weights of three films were taken and the weight variation was calculated. 
11.3. FOLDING ENDURANCE 
Folding endurance of the film was determined by repeatedly folding one patch 
at the same place till it broke or folded up to 300 times manually, which was 
considered satisfactory to reveal good film properties. The number of times of film 
could be folded at the same place without breaking gave the value of the folding 
endurance. This test was done for three films. 
11.4. DRUG CONTENT UNIFORMITY 
A film was cut into three pieces of equal diameter were taken in separate 100 
ml of pH 6.8 phosphate buffer was added and continuously stirred for 24 h. The 
solutions were filtered, suitably diluted and analyzed at 313 nm in a UV 
Spectrometer. The average of drug content of three films was taken as final reading. 
11.5. IN VITRO RELEASE STUDY 
The drug release studies were performed with USP dissolution test apparatus. 
(Paddle method). The USP dissolution apparatus was thermostated at the temperature 
of 37±1o C and stirred at rate of 50 rpm. Each film was fixed on a glass slide with the 
help of cyanoacrylate adhesive so that the drug could be release only from upper face. 
Then the slide has immersed in the vessel containing 500 ml of pH 6.8 phosphate 
buffer solution. 
The aliquots of 1 ml were withdrawn at the time interval of every hour and 
replaced with equal volume of dissolution medium. The sink condition was 
maintained throughout the study. The samples were analyzed at 313 nm in a UV-VIS 
Spectrometer and cumulative amount of drug release at various time intervals was 
calculated. 
11.6. RELEASE KINETICS 
The obtained results in these formulations were plotted in various model 
treatment are as follows. i.e. Cumulative percentage release of drug Vs Square root of 
time (Higuchi’s) and Log cumulative percentage release Vs Log time (Peppas). The 
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formulations F1, F2, F3, F4, F5 and F6 comparative plotted graphs of Higuchi’s and 
Peppas were shown in the Fig. 2 and 3 respectively. 
To find out the mechanism of drug release from hydrophilic matrices, the 
invitro dissolution data of each formulation with different kinetic drug release 
equations. Namely Zero order: Q=K0t; Higuchi’s square rate at time: Q=KHt1/2 and 
Peppas: F=Kmtn, where Q is amount of drug release at time t, F is Fraction of drug 
release at time t, K0 is zero order kinetic drug release constant, KH is Higuchi’s 
square root of time kinetic drug release constant, Km is constant incorporating 
geometric and structural characteristic of the films and n is the diffusion exponent 
indicative of the release mechanism. The correlation coefficient values (R2) indicate 
the kinetic of drug release was zero order and the mechanism of drug release was by 
peppas model indicates the super case II transport evidenced with diffusion exponent 
values (n) Table. 3. 
11.7. STABILITY STUDIES 
The optimized films of cimetidine with backing membrane were placed in an 
amber coloured bottle with aluminium cap as a closure. It was tightly sealed and kept 
in the incubator maintained at 40 ± 2 °C and 75 ± 5% RH. The stability studies were 
carried out for a period of 3 months. Samples were collected at 0, 15, 30, 45, 60 and 
90 days and observed for appearance and drug content of the films was investigated in 
triplicate. 
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12. RESULTS AND DISCUSSION 
12.1. Pre formulation Studies: 
12.1.1. Organoleptic Properties: 
These tests were performed as per the given procedure and the results are 
illustrated.  
Table 11: Organoleptic Properties 
The result complies as per specifications. 
12.1.2. Melting Point: 
Table 12: Melting point 
 
                        The Result indicates that Cimetidine was pure one. 
12.1.3.  Solubility: 
           The solubiliy was determined and the result is illustrated below 
Table 13: Solubility 
                                           
                      
 
 
 
 
The result complies as per specifications. 
12.2. Drug-excipient compatibility studies: 
Discussion: 
The FT-IR peaks were observed that there is no change in the spectrum 
representing that there is no interaction between the drug and polymers and other 
excipients. These peaks play a vital role with respect to drug release.
Test Specification/Limits Observations 
Color White to off White  powder White crystalline powder 
Taste Bitter Bitter 
Odour Odorless Odorless 
Material Melting point range Result 
Cimetidine 140-144 Complies 
Test Specification Result 
Solubility 
soluble in methanol and acetic 
acid,sparingly soluble in 
ethanol,slightly soluble in water, 
insoluble in diethyl ether 
Complies 
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Figure 7: FTIR graph of Cimetidine 
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Figure 8:: FTIR graph of Cimetidine and polymer(PVA) 
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Graph 9: FTIR of Cimetidine and Polymer (PVA+HPMC+SCMC) 
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               Table no.14: Physical Evaluation of Buccal Films of Cimetidine 
 
Thickness:  
The film thicknesses were observed by using digital vernier caliper and found 
to be in the range of 0.25±0.008 mm to 0.34±0.022 mm. 
 Weight:  
The weight of films was found to be in the range of 205.4 ±1.62 mg to 
218.4±2.08 mg. 
Folding Endurance:  
The folding endurance was found to be highest for formulation F5 (315±6.3) 
and the lowest for formulation F4 (279±8.9). It was found that the folding endurance 
was increased with the addition of PVA with HPMC. 
 
 
 
 
 
 
 
Formulation 
Code 
Thickness 
(mm)±S.D 
 
Weight of 
the film 
(mg)±S.D 
 
Folding 
endurance 
±S.D 
Drug 
content(mg)±S.D 
 
%Cumulative 
drug release 
after 12h 
F1 0.27±0.036 205.4±1.62 280±3.6 98.0±1.0 98.5±0.76 
F2 0.25±0.008 215.3±1.32 301±5.5 91.92±0.11 99.2±0.115 
F3 0.31±0.014 208.6±1.52 290±6.6 97.16±0.348 90±0.74 
F4 0.28±0.007 214.2±3.05 279±8.9 89.50±0.5 91.3±1.43 
F5 0.34±0.022 216.1±1.52 315±6.3 98.96±0.057 88.5±1.47 
F6 0.33±0.013 218.4±2.08 310±7.3 92.75±0.476 93.4±1.12 
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Table no.15: Invitro cumulative drug release studies of cimetidine buccal patches 
Time 
% Cumulative drug release ±S.D 
F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
2 9.5 8.3 8.2 8.5 7.5 7.8 
4 11.3 23.5 20.2 20.2 20 15.4 
6 54.5 41.8 42.3 43.7 35.7 26.7 
8 81.2 68.7 65 65.1 55.1 43.5 
10 93 89.7 85 85.1 78.2 59.6 
12 98.1 99.8 90 90.7 88 92.4 
 
Figure 10 -In vitro drug release profiles of formulation F1, F2, F3, F4, F5 and F6 
 
The cumulative percentage drug release was observed in the formulation F1 
after 10 h was found to be 98.12 %. 
The cumulative percentage drug release was observed in the formulation F2 
and F3 after 10 h was found to be 89.8 % and 85 % respectively. 
The cumulative percentage drug release was observed in the formulation F4 
and F5 after 12 h was found to be 90.7 % and 88.0 % respectively. 
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Figure 11 - Cumulative % Release of Formulation F2 
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Zero Order Kinetic Model: 
Table no.16: Zero Order Kinetic Model 
Time (Hr) cumulative % drug released 
0 0 
2 8.3 
4 23.5 
6 41.8 
8 68.7 
10 89.7 
12 99.8 
 
Figure 12 - Cumulative % Release of Formulation F2 
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First Order Release Kinetics 
Table no.17: First Order Kinetic Model 
Time (Hr) log Cumu % drug remainining 
0 2.000 
2 1.962 
4 1.884 
6 1.765 
8 1.496 
10 1.013 
12 0 
 
Figure 13 - Cumulative % Release of Formulation F2 
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Higuchi Model: 
Table no.17: Higuchi Model 
Square root 
time 
cumulative % drug 
released 
0.0 0 
1.4 8.3 
2.0 23.5 
2.4 41.8 
2.8 68.7 
3.2 89.7 
3.5 99.8 
 
Figure 14 - Cumulative % Release of Formulation F2 
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KORSEMEYER PEPPAS MODEL: 
Table no.18: Korsemeyer Peppas Model 
log time log Cumu % drug 
released 
0.000 0.000 
0.301 0.919 
0.602 1.371 
0.778 1.621 
0.903 1.837 
1.000 1.953 
1.079 1.999 
 
Figure 15 - Cumulative % Release of Formulation F2 
 
 
 
 
 
 
R² = 0.9673 
0.000
0.500
1.000
1.500
2.000
2.500
0.000 0.200 0.400 0.600 0.800 1.000 1.200
lo
g
 C
u
m
u
 %
 d
ru
g
 r
e
le
a
se
d
  
log time 
KORSEMEYER PEPPAS MODEL 
RESULTS AND DISCUSSION 
Department of Pharmaceutics Page 75 
Stability study: 
Table 19: Stability study of cimetidine buccal films at 40 ± 2 °C and 75 ± 5% RH 
Time 
(days) 
0 15 30 45 60 90 
% drug 
remaining 
94.71 94.12 93.43 93.02 92.67 91.89 
 
 
Optimized formulation did not show any physical changes during the study 
period and also exhibit excellent drug content over the storage period. 
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13. SUMMARY 
The Cimetidine buccal films were prepared by the method of solvent casting 
technique, using polymers of Hydroxy Propyl Methyl Cellulose (HPMC), SCMC, and 
Poly Vinyl Alcohol (PVA) were dispersed in ethanol and water and glycerol which 
served the purpose of plasticizer. The prepared Cimetidine buccal films were 
evaluated or characterized based upon their physical characteristics like thickness, 
weight, folding endurance studies were performed. Thickness of the formulation 
varied from 0.27± 0.036 to 0.34±0.022 mm. Weight of the formulated buccal films 
ranges from 208.6±1.52 to  218.4± 2.08 mg. Folding endurance ranged from 280±3.6 
to 315±6.3.The percent drug content among all the formulations ranged from 92.75± 
0.476 to 98.96± 0.057. The cumulative drug release values showed a gradation from 
88.5 % to 99.2 % showing the better controlled release properties. The correlation 
coefficient values (R2) indicate the kinetic of drug release was zero order and the 
mechanism of drug release was by peppas model indicates the Fickian transport 
evidenced with diffusion exponent values (n). 
The optimized films showed no significant changes in the % drug remaining 
after the stability studies for 3 months. 
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14. CONCLUSION 
The buccal mucosa offers several advantages for controlled drug delivery for 
extended periods of time. The mucosa is well supplied with both vascular 
and lymphatic drainage and first-pass metabolism in the liver and pre-systemic 
elimination in the gastrointestinal tract are avoided. The area is well suited for a 
retentive device and appears to be acceptable to the patient. With the right dosage 
form design and formulation, the permeability and the local environment of the 
mucosa can be controlled and manipulated in order to accommodate drug permeation. 
Buccal drug delivery is a promising area for continued research with the aim of 
systemic delivery of orally inefficient drugs as well as a feasible and attractive 
alternative for non-invasive delivery of potent peptide and protein drug molecules. 
However, the need for safe and effective buccal permeation/absorption enhancers is a 
crucial component for a prospective future in the area of buccal drug delivery. The 
formulations of cimetidine bioadhesive buccal film is promising one as the controlled 
drug delivery, improves bioavailability and the dose of cimetidine could be minimized 
and hence prevent the colonic degradation of cimetidine by colonic bacteria. 
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